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TISSUE-RESIDENT MYELOID-DERIVED SUPPRESSOR CELLS MODULATE 
IMMUNE HOMEOSTASIS IN HEALTHY ADIPOSE  
Katlin B. Stivers 
June 10th, 2020 
Our goal with this study was to gain insight into the homeostatic immune 
cell network in healthy adipose tissue. Specifically, we sought to determine if the 
immature myeloid cells found in healthy and inflamed adipose were, in fact, tissue-
resident myeloid-derived suppressor cells (MDSCs). Using various in vitro and in 
vivo methods, we have uncovered a population of CD11bHi Ly6CHi Ly6G- MDSCs 
resident in healthy adipose tissue. To the best of our knowledge this is the first 
time that these cells have been investigated and described in healthy adipose 
tissue. Systemic MDSC depletion lead to the accumulation of CD4+ CD44+ CD62L- 
TEM in the adipose of otherwise healthy mice and altered the surface markers 
expressed by adipose tissue-resident macrophages. Furthermore, we found that 
losing MDSCs significantly changed the transcription levels of multiple 
immunomodulatory genes in the adipose stromal cell compartment and whole 
adipose tissue. Taken together, this suggests that adipose-resident MDSCs are 
one of the key players in the adipose tissue immune cell network, preventing 
iv 
aberrant, inflammatory TEM proliferation and modulating the suppressive 
phenotype of adipose tissue-resident macrophages. 
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CHAPTER 1: INTRODUCTION 
Adipose Tissue 
Adipose tissue (AT) is a loose connective tissue that serves as an energy 
storage depot, using fatty acid oxidation reactions to store excess glucose and, 
when necessary, release it back into circulation.  This tissue has a multitude of 
other endocrine, metabolic, and thermoregulatory functions. In mammals, adipose 
depots are distributed throughout the body and are divided into two main 
categories: brown and white. Mainly found in infants, brown AT (BAT) uses stored 
lipids to produce heat and regulate body temperature. In adults the majority of 
depots are white adipose tissue (WAT) which can also contribute to 
thermoregulation by developing a “beige” phenotype [1]. For the most part 
however, WAT stores and releases energy for systemic use in response to 
changes in insulin and glucagon levels, respectively.  
While adipocytes are the main cellular unit of AT, they are only 20 – 40% of 
the total cells found in the tissue, with adipose stromal cells accounting for the 
remaining 60 – 80% of cells [2]. In lean, healthy individuals this stromal-vascular 
cellular fraction (SVF) contains a wide-array of endothelial cells, mesenchymal 
stem cells, pre-adipocytes, and immune cells. Altogether they are integral 
regulators of adipose tissue homeostasis. SVF cells promote angiogenesis; 
release AT-modulating molecular factors such as cytokines and hormones; and 
produce the extracellular matrix elements necessary to maintaining tissue integrity. 
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The exact distribution of these cell types differs between adipose depots and may 
depend upon its physiological function [3-8]. Compared to visceral AT depots, the 
omental AT appears to function more as a tertiary lymphoid tissue than it does an 
energy storage depot. For instance, special fat-associated lymphoid clusters in 
omental AT act almost as loosely organized germinal centers, where tissue 
resident dendritic cells induce antigen-specific B cell responses [9-12].  Over the 
last 20 years, we have begun to recognize the importance of the SVF immune cell 
compartment in not only driving obesity-induced visceral AT inflammation, but also 
maintaining in modulating the day-to-day functions of this tissue [2].  
The Essential Role of Inflammation in Healthy Adipose Tissue Homeostasis 
Catering to the metabolic needs of an organism is a dynamic process. As 
blood glucose levels increase or decrease, adipocytes initiate lipogenesis or 
lipolysis reactions to sequester or release energy, respectively. Accompanying the 
ebb and flow of lipids being stored or released are requisite fluctuations in the 
physical size of adipocytes. Practically, this calls for near constant extracellular 
matrix (ECM) remodeling in the adipose to accommodate these physical changes. 
Importantly, Wernstedt Asterholm, Tao [13] (2014) found that as adipocytes 
initiated either of these metabolic reactions, they simultaneously upregulated their 
expression of TNFα. The subsequent inflammatory cascade eventually 
precipitated the breakdown of the surrounding ECM, allowing adipocytes to 
expand or contract as necessary. This finding was surprising given that this 
cascade was observed in healthy, chow-fed mice and that both TNFα upregulation 
and AT inflammation are typically associated with obesity. Furthermore, an 
3 
adipocyte specific inhibition of TLR4-, TNFα-, and IL1β-mediated signaling led to 
significant metabolic dysfunction in otherwise healthy animals and enhanced the 
metabolic consequences of a high-fat diet compared to WT controls. Implicating 
that this inflammatory pathway is physiologically necessary for the maintenance of 
healthy adipose tissue homeostasis [13].  
Further complicating our perception of inflammatory dynamics in AT is the 
ambiguous role of TNFR1 signaling in metabolic health and disease [14]. For 
instance, transgenic knockout of TNFR1 gained significantly more weight on a 
normal diet than wild-type controls confirming the findings from the aforementioned 
study concerning the integral nature of TNF-mediated signaling in maintaining 
healthy metabolic homeostasis. When fed a high-carbohydrate diet however, 
these TNFR1 knockout mice had improved insulin sensitivity and had reduced 
adiposity compared to wild-type controls on the same diet, highlighting the 
deleterious effects this same signaling pathway can have in a pathological setting 
[14]. Altogether, these studies have brought to light the important role that acute 
inflammation, as reflected by TNFα signaling, plays in the day-to-day functions of 
this dynamic tissue and calls for a reassessment of the disease-centric way in 
which AT inflammation is most often viewed. 
Besides the requirement for TNF-α mediated signaling, ECM remodeling 
could also be a constitutive source of toll-like receptor (TLR) ligands in the tissue 
[15, 16]. By-products of ECM degradation have the potential to be both pro- and 
anti-inflammatory, depending upon the microenvironmental context and through 
which TLRs they mediate their signals [15]. In AT specifically, these molecules are 
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associated with the obesity-induced inflammation [17, 18]. However, even under 
normal conditions, AT is constantly being degraded and remodeled, producing 
inflammatory-like conditions, yet healthy tissue is not considered to be chronically 
inflamed. What prevents these pro-inflammatory molecules and the signaling 
pathway involved in AT remodeling from developing into the pathological 
inflammation observed in metabolic diseases? 
Adipose-Resident Immune Cell Network 
According to Wernstedt-Asterholm et al [13, 19], “immunological fitness” is 
the saving grace of this tissue. Immunological fitness is a measure of an 
organism's (or tissue's) ability to efficiently mount and subsequently resolve an 
effective immune response. In this case it applies to the acute TNFα-mediated 
inflammatory response required for ECM remodeling in healthy AT. If this 
immunological fitness is compromised, then the tissue is no longer able to cope 
with these acute inflammatory responses and develops metabolic complications, 
as demonstrated by the various transgenic knockout models used in this study 
[13]. 
Going one step further, AT immunological fitness is, at its core, a function 
of the tissue-resident immune cell network. This network is inherently 
immunomodulatory in healthy AT and most likely evolved as a means to efficiently 
quell the intermittent acute inflammatory responses required to properly 
accommodate lipid storage and release by adipocytes. Adipose tissue-resident 
macrophages (ATMs) make up the largest percentage of these cells by far [20, 
21]. ATMs are considered true "tissue-resident" macrophages as they are fetal 
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liver derived [22], do not develop from circulating monocytes, and the population 
undergoes self-renewing in situ proliferation [23].  
Classically, murine ATMs are defined as F4/80+ CD301+ CD206+ CD11c- 
CD64- and exhibit transcriptional and functional traits associated with “M2-like” 
polarization. Recently, the boundaries of this definition have expanded as more 
comprehensive, single-cell level studies have uncovered heterogeneity within this 
macrophage compartment in healthy AT [24, 25]. Finding surface marker 
heterogeneity among this population is not that surprising considering the extreme 
sensitivity of macrophages to microenvironmental cues and the dynamic AT 
microenvironment. On the other hand, their functional heterogeneity within the 
same tissue is unexpected. These cells can perform a multitude of tasks required 
for AT to function properly, including clearing dead cellular debris and directing 
ECM remodeling efforts [20]. Specific ATM functions may also be dependent upon 
their location within the tissue. One study identified a subset of vasculature-
associated ATMs with enhanced endocytic capacity compared to other ATM 
subsets [25]. Additionally, ATMs found around hypertrophic adipocytes appear to 
act as "clean-up crews” phagocytosing excess lipids released by the adipocyte [26, 
27]. Similarly, fatty acids released during weight loss-induced lipolysis are taken 
up and stored by ATMs [28]. A common theme among all ATM subsets however, 
is that obesity profoundly alters their phenotype and function, steering them 
towards a more pro-inflammatory, “M1-like” polarization state [20, 21, 29]. 
Monocyte-derived macrophages also infiltrate the tissue exacerbating and 
sustaining the pro-inflammatory nature of the obese AT microenvironment [20]. 
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ATMs maintain their "M2” status in healthy adipose via cytokine signaling 
and cross-talk with AT-resident eosinophils and innate lymphoid type 2 cells 
(ILC2s) [30]. IL-33 signaling recruits and activates ILC 2s into the adipose, where 
they regulate the immunosuppressive phenotypes of many other SVF cell types 
[31-33]. Their production of IL-5 and IL-13 is especially important for the resiliency 
of the ATM phenotype against inflammatory challenge [30, 34]. IL-5 also recruits 
eosinophils into the tissue. Usually associated with promoting rapid type II allergy 
responses, these innate granulocytes serve a more regulatory role in adipose. 
Eosinophils are one of the primary sources of IL-4 in AT, without which ATMs begin 
to switch towards a more pro-inflammatory “M1” phenotype [30, 35]. 
Adaptive immune cells also participate in the AT immune cell network in the 
form of both B and T lymphocytes [2]. The B cell compartment in lean AT is 
primarily made up of regulatory B cells that produce IL-10 and influence ATM 
phenotype [36, 37], although not much work has been done to elucidate any 
additional notes these cells may play in maintaining AT homeostasis.  
Much more is known about the T cells found in adipose, albeit through the lens 
of obesity. For instance, obesity is perpetuated by the infiltration of both CD4+ and 
CD8+ T cells, with a limited TCR repertoire, into the tissue [38]. There are CD4+ T 
cells in lean adipose as well. Their origin, function, and specificity however have 
yet to be discerned. In mice, depending upon the AT depot, the majority of these 
cells exhibit a CD44+ CD62L- effector memory phenotype and are capable of 
mounting a Th1-type response upon non-specific co-stimulation [39, 40]. While the 
antigen specificity of these memory T cells is unknown, there is growing evidence 
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that the WAT may act as a reservoir for pathogen-specific memory T cells [38, 39, 
41-48]. For example, Toxoplasma gondii and Yersinia pseudotuberculosis-specific 
effector and tissue-resident memory T cells were found in adipose [39]. Moreover, 
these populations were self-sustaining, long-lived, and capable of mounting an 
effective response upon reinfection. A similar population has also been observed 
in human adipose, where HIV positive T cells have been identified even in patients 
with undetectable viral loads in circulation [42].  
With aging, in both murine and human adipose, the phenotypic distribution of 
CD4+ T cells shifts, with the majority transitioning from memory T cells to regulatory 
T cells (TRegs) [39, 49, 50]. TRegs accumulate in AT with age. For the most part, 
these cells appear to serve a protective purpose in the tissue by influencing the 
suppressive phenotypes of other AT immune cells via TGFβ and IL-10 production 
[2]. Furthermore, the addition of exogenous TRegs in obese mice alleviates some of 
their metabolic symptoms [50]. This may not always be the case however, as 
systemic ablation of TRegs actually prevents aging-related metabolic syndromes 
from developing [49]. 
Even though our understanding of the healthy adipose immune cell network is 
relatively limited, it is still clear that these cells play a major role in modulating 
homeostasis in this tissue and in protecting it from the pro-inflammatory challenges 
it faces as a consequence of its dynamic physiologic functions (Figure 1.1). 
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Figure 1.1: Homeostatic Immune Cell Network in Healthy Adipose Tissue. 
Dynamic immune cell interplay prevents T cell-mediated adipose tissue 
inflammation under normal dietary pressures. ATM: adipose tissue-resident 
macrophage. ECM: extracellular matrix. AT: adipose tissue. DAMPs: damage-
associated molecular patterns. FFA: free-fatty acids. TCR: T cell receptor. TLR: 
toll-like receptor.  
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Immunosuppressive Abilities of SVF 
The immunomodulatory and tissue remodeling properties of these non-
adipocyte cells are currently being investigated for various cell-based anti-
inflammatory and wound-healing therapeutic applications [51-59]. By studying the 
impacts SVF-based cellular therapies have on local immune responses we can 
gain insight into the nature of the immunomodulatory microenvironment that these 
cells create in their native tissue. 
Initially, many of these studies revolved around adipose-derived 
mesenchymal stem cells (AD-MSCs) which are derived from SVF following several 
days of culture [60]. Similar to bone marrow-derived mesenchymal stem cells AD-
MSCs possess potent regenerative and immunomodulatory abilities, but are much 
more accessible, making them a promising alternative to bone marrow MSC-based 
treatments [61-68]. In solid organ transplantation, donor-derived AD-MSCs have 
been shown to suppress activated recipient T cell responses and reduce the 
severity of acute rejection in rat models of allogeneic liver [69] and kidney [70] 
transplantation. Additionally, multiple post-transplant injections of donor-derived 
AD-MSCs have been shown to prolong the survival of a vascularized-composite 
tissue allograft (VCA) by increasing the number of circulating TRegs and reducing 
allograft-infiltrating leukocytes [64, 71]. These cells have also been associated with 
the accumulation of immunosuppressive “M2”- like macrophages [72-74]. One 
study demonstrated that AD-MSCs reduced aortic inflammation in a murine 
aneurysm model by directly inducing M2 polarization [75]. Other 
immunomodulatory functions of these cells include suppressing activated B cell 
production of immunoglobulin [60], as well as preventing dendritic cell (DC) 
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differentiation and downregulating their expression of co-stimulatory molecules 
[63, 67, 76]. 
Freshly isolated SVF cells also possess substantial regenerative and 
immunosuppressive properties, but do not require extensive in vitro enrichment or 
expansion to be used therapeutically [51-54]. Compared to AD-MSCs, SVF-based 
therapies are equally as effective at treating inflammation and promoting wound 
healing [55-57, 59, 77-81]. In a murine model of multiple sclerosis, SVF cells 
increased Treg recruitment to sites of inflammation to a similar, if not greater, 
degree than AD-MSCs [54, 55]. Clinically, SVF has been used to treat systemic 
sclerosis [82], peripheral vascular disease [58], and, in one case, industrial X-ray 
injury [83]. In each of these studies, SVF cells reduced circulating levels of 
inflammatory cytokines and disease symptom severity in general [58, 82, 83]. 
Recently, clinical trials performed at the University of Louisville have shown 
promising initial results using freshly isolated, autologous SVF cells as a means to 
prevent and treat acute VCA rejection [84]. Interestingly, the innate heterogeneity 
of the SVF isolate makes it difficult to develop a standardized cellular product for 
regulatory approval. However, this same heterogeneity may also be the very 
aspect behind the robust therapeutic efficacy of SVF-based treatments as the in 
vivo crosstalk that promotes their anti-inflammatory properties in adipose likely 
continues after isolation and may preserve their immunomodulatory character 
when transplanted into an inflamed microenvironment.  
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Myeloid-Derived Suppressor Cells 
In our lab, we focused on developing an SVF-based therapy to improve 
vascular function following injury. We found that treatment with the SVF improved 
vasodilation and reduced immune cell infiltration into the wall of the injured vessel 
[85]. Moreover, the SVF isolate lost many of its beneficial effects when the CD11b+ 
cells were depleted. Further flow cytometric characterization of these CD11b+ cells 
revealed that a portion also expressed Gr1, a marker typically used to identify 
neutrophils. However, given that the SVF utilized in these experiments was 
isolated from healthy mice and neutrophil numbers are very low, it is unlikely that 
these CD11b+ Gr1+ cells were neutrophils [86]. Another, albeit less conventional, 
candidate are myeloid-derived suppressor cells (MDSCs). 
MDSCs: An Overview 
MDSCs are classically defined as a heterogeneous population of potently 
immunosuppressive, CD11b+ Gr1+ immature myeloid cells. MDSCs were first 
identified as a major contributor to the anti-inflammatory nature of the tumor 
microenvironment (TME) and have since been described performing similar 
functions in several chronic inflammatory and autoimmune diseases [87-89]. They 
have also been shown to promote allogeneic and maternal-fetal tolerance [90-92]. 
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous collection 
of “immature”, or non-terminally differentiated, CD11b+ Gr1+ cells that accumulate 
at sites of chronic inflammation. They can be further classified into two 
subcategories based on their expression of Ly6C and Ly6G: Polymorphonuclear 
PMN-MDSCs (CD11b+ Ly6CInt/Low Ly6G+) and Monocytic M-MDSCs (CD11b+ 
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Ly6CHi Ly6G-) [93]. Despite their phenotypic heterogeneity, these cells possess 
one common trait. They are potently immunosuppressive, targeting both antigen-
specific and non-specific inflammatory responses. MDSCs were first identified as 
one of the primary cell types responsible for the impaired immune surveillance 
observed in the tumor microenvironment (TME) and have since been described 
performing similar functions in several chronic inflammatory conditions. As such, 
MDSCs are almost exclusively associated with disease and the dysfunctional 
resolution of chronic inflammation [89, 94-99]. Since the majority of studies on 
MDSCs revolve around the inhibition of tumoricidal responses, the 
immunosuppressive activity of these cells is often considered to be an abnormal 
hijacking of the emergency myelopoiesis response that would not develop under 
healthy, steady-state conditions.  
Over the last decade evidence has accumulated supporting the idea that 
MDSCs may act as the innate immune system's equivalent of regulatory T cells, 
protecting tissues from the detrimental effects of chronic inflammation [97]. For 
instance, these cells have been identified in chronic inflammatory conditions such 
as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis [89, 94-
99]. In each of those settings, MDSC numbers are correlated with improved 
disease outcomes as they downregulate activated T cell responses, promote "M2" 
macrophage polarization, and enhance angiogenesis in the inflamed tissue 
microenvironment. Additionally, these contentious cells were found to play an 
integral role in successful, full-term pregnancies by establishing and maintaining 
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maternal-fetal tolerance. Their tolerogenic activities may also play a role is 
prolonging graft survival in allogeneic transplantation [90-92].  
The diverse nature of both MDSC phenotype and function has made it 
difficult to develop a universally applicable definition for these cells. In 2016, MDSC 
researchers developed a characterization algorithm (Table 1.1) to rectify this [100]. 
This strategy uses a combination of phenotypic, biochemical, and functional traits 
to differentiate MDSCs from other myeloid cell types such as monocytes and 
neutrophils.  
Table 1.1: Brontë et al (2016) Algorithm for Characterizing MDSCs. 
MDSC Effector Mechanisms 
The primary effector function of these cells is the inhibition of activated T 
cell proliferation through a variety of direct and indirect mechanisms. However, 
their influence is not limited to activated T cell responses, as they have also been 
found to modulate macrophage phenotype, promote angiogenesis, and induce the 
development of regulatory T cells in the periphery [93, 98]. 











Immune suppressive activity 
Expression of characteristic molecular markers: Arginase, iNOS, IL-10, 
TGFβ, IL-4R 
Expansion of the myeloid compartment under pathological conditions. 
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It's likely that no single MDSC utilizes more than one of these effector 
mechanisms at any given time, however the heterogeneous nature of the total 
MDSC population may mean that many of these suppressive activities could be 
represented within a single TME [101-103]. Moreover, differences between tumor 
types strongly affects the cell types and soluble proteins found around the tumor 
which means that different tumor types elicit different MDSC responses. The 
immature nature of MDSCs could also contribute to their functional plasticity as 
they may be able to respond to environmental signals more quickly than a 
terminally differentiated cell. 
MDSC Effector Mechanisms: Nutrient Deprivation 
Pro- and anti- inflammatory responses are often described in terms of 
signaling cascades or receptor-ligand interactions. MDSCs however have 
developed a potent, somewhat round-about means with which to suppress 
proliferative, inflammatory T cell responses. In order to divide, T cells must import 
certain amino acids or their precursors from the local microenvironment. MDSCs 
can then sequester these resources, preventing T cells from being able to 
proliferate further. Arginine and cysteine are the primary targets of this insidious 
siege. 
Excessive arginine consumption is one of the most straightforward 
examples of nutrient deprivation-mediated immune suppression. In the TME, 
MDSCs upregulate their expression of induced Nitric Oxide Synthase (iNOS) and 
Arginase 1 (Arg1), both of which use L-arginine (L-Arg) as their primary substrate. 
The increased activity of these two enzymes eventually depletes L-Arg from the 
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surrounding microenvironment. Without access to this essential amino acid, 
effector T cells around the tumor cannot proliferate and eventually downregulate 
surface expression of the CD3 ζ chain required for proper T cell receptor (TCR) 
signaling in response to antigen recognition [104]. This essentially leaves T cells 
“blind” to the continued presence of tumor-derived antigens. Eventually, this 
prolonged lack of antigen-mediated signaling leads to a significant reduction in 
effector T cell activation and proliferation. L-arginine sequestration plays such a 
vital role in MDSC-mediated immune suppression that genetic deletion of just one 
kind of arginine transporter weakened their ability to inhibit activated T cell 
proliferation in vitro [105]. In vivo CAT2-/- mice, which have dysfunctional cationic 
amino acid transporter and cannot import arginine, also had reduced tumor growth 
compared to control animals which was attributed to a relatively greater number of 
tumor-infiltrating lymphocytes and diminished iNOS activity in the MDSCs 
themselves [105] (Figure 1.2). 
Along with arginine deprivation, MDSCs can also significantly diminish the 
amount of cysteine and cystine available in the TME [106]. T cells lack the xc- 
Cystine-Glutamate antiporter (xc-) required to import cystine from extracellular 
sources. They can, however, acquire cysteine from their local environment via the 
Alanine-Serine-Cysteine transporter-1 (Asc-1), a transmembrane neutral amino 
acid transport protein. Once inside the cell, cysteine is reduced to the requisite 
cystine, essential for continued protein synthesis. In an inflammatory response, 
antigen presenting cells (APCs) are thought to be the primary source of 
extracellular cysteine taken up by T cells. MDSCs on the other hand only possess 
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xc- and do not export release oxidized cysteine back into their surroundings. 
Additionally, APC:MDSC crosstalk causes APCs to downregulate expression of 
Asc-1 hindering their ability to export cysteine. The rapid uptake and consumption 
of cystine by MDSCs combined with a reduced rate of cysteine export by APCs 
drastically impacts the amount of cysteine available for use by proliferating, 
effector T cells. Without an available pool of this amino acid, activated T cells 
downregulate expression of the CD3 ζ chain resulting in proliferative arrest (Figure 
1.2). 
MDSC Effector Mechanisms: Oxidative Stress 
Apart from the over consumption of L-Arg, MDSCs use iNOS and Arg-1 to 
manipulate inflammatory immune responses by inducing oxidative stress within 
the TME (Figure 1.3). Co-expression of these enzymes, along with NADPH 
oxidase, allows MDSCs to produce reactive oxygen (ROS) and nitrogen species 
(RNS) that have various suppressive effects [107]. These induce downstream 
effects that can be divided into two broad categories: signal interruption and 
impaired trafficking. MDSC-induced oxidative stress can manifest in several ways 
since ROS and RNS do anything from directly damaging the tissue to influencing 
the folding of individual proteins. In terms of T cell-specific impacts, PMN-MDSC-
produced hydrogen peroxide reduces T cell expression of the CD3 ζ chain [108] 
(Figure 1.3 a), while M-MDSC-produced peroxynitrite incapacitates IL-2 receptors 
via nitrosylation [109] (Figure 1.3 b). Either way T cell sensitivity to various 
activation signals is greatly diminished. Similarly, peroxynitrite can interfere with T 
cell migration by nitrosylating CCL-2 on the surface of T cells. This alters the 
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conformation of this chemokine, effectively preventing the cell from migrating into 
the tumor itself [110] (Figure 1.4 a).  
MDSC Effector Mechanisms: Cytokines and Direct Cell-Cell Interactions 
Although Ros and RNS are powerful mediators of immune suppression, 
they are not the only molecular tools MDSCs have at their disposal. These cells 
use both surface and soluble proteins to downregulate the inflammatory, anti-
tumor responses of various cell types in the TME. ADAM17 cleaves L-selectin 
(CD62L) on the surface of T cells, downregulating its expression and preventing 
their trafficking to the draining lymph nodes [111] (Figure 1.4 b). MDSCs can also 
induce T cell apoptosis by expressing Gal9 on their surface, which interacts with 
TIM3 on T cells [112] (Figure 1.4 b). MDSC-produced cytokines can also directly 
influence the pro-inflammatory nature of cells in the TME (Figure 1.5). There is 
evidence that membrane bound TGF-β on MDSCs prevents NK cells from 
mounting tumoricidal responses [113]. MDSCs also produce IL-10 which steer 
macrophage polarization towards the tumor preserving, immunosuppressive "M2" 
phenotype [114, 115]. Additionally, IL-10 production by MDSCs reduces TLR4 
expression on the surface of dendritic cells (DC). Without this pattern recognition 
receptor, DCs cannot recognize tumor-induced tissue damage and stop producing 
IL-12 which would otherwise be used to promote pro-inflammatory, antigen-
specific T cell responses [115]. 
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MDSC Effector Mechanisms: MDSCs and TRegs 
MDSCs within the TME directly modulate the functional phenotypes of 
various innate immune cells. This influence extends to adaptive immunity as well, 
going beyond simply preventing antigen-specific, pro-inflammatory T cell 
responses. MDSCs have the ability to activate and induce TReg differentiation in 
the periphery and activate natural TReg already is circulation [107]. The exact 
mechanisms behind this have yet to be uncovered, but there are several potential 
candidates. These include the production of cytokines such as IFNγ, IL-10, and 
TGFβ [116]; CD40-CD40L-mediated cell-cell interactions [117]; and their 
increased arginase activity [118]. No matter what the mechanism is behind 
MDSC:TReg interactions, it is clear that induction or a clonal expansion of these 
cells is a powerful tool that MDSCs can use to manipulate anti-tumor responses in 
their microenvironment.  
Despite the ambiguous nature of these cells, one thing remains clear, 
wherever there is prolonged chronic inflammation or the persistent need for 
immune tolerance, suppressive myeloid cells accumulate. This strongly supports 
the idea that these cells are less of a pathological consequence to an immune 
insult and more of a physiologically normal innate response to prevent further 
inflammation-induced tissue damage.  
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Figure 1.2:  MDSC-mediated nutrient deprivation downregulates activated T 
cell proliferation in the tumor microenvironment. MDSCs disrupt 
cystine/cysteine homeostasis and overconsume arginine in their local 
microenvironment, preventing T cells from acquiring these amino acids, essential 
for their continued proliferation. MDSC: myeloid-derived suppressor cell. TAM: 
tumor-associated macrophage.  
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Figure 1.3: MDSCs use oxidative stress responses to prevent T cell 
activation and subsequent proliferation in the tumor microenvironment. (a) 
NADPH oxidase and iNOS activity increases hydrogen peroxide levels in the 
microenvironment, prompting T cells to downregulate CD3ζ expression and 
ultimately disrupting their ability to respond to antigen. (b) Peroxynitrite deforms 
surface proteins such as T cell receptors (TCR) and IL-2R. In the absence of 
continued IL-2 signaling and antigen recognition. T cell proliferation grinds to a 
halt. MDSC: myeloid-derived suppressor cell.  
21 
Figure 1.4: MDSCs disrupt lymphocyte trafficking into and out of the tumor 
microenvironment. (a) MDSC-mediated nitrosylation of CCL2 interrupts the 
signaling pathway that recruits CD8+ cytotoxic T cells into tumor tissue. (b) MDSCs 
interact directly with T cells to prevent their migration into the lymph nodes by 
disrupting CD62L expression or promoting cell death. MDSC: Myeloid-derived 
suppressor cell. TCR: T cell receptor.  
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Figure 1.5: Immunomodulatory effects of MDSCs on innate immune cells. In 
addition to T cells, MDSCs can manipulate the inflammatory responses of other 
cells in the tumor microenvironment using contact-dependent and independent 
mechanisms. MDSC: myeloid-derived suppressor cell. TAM: tumor-associated 




Since their discovery the possible origins of MDSCs has been a subject of 
speculation. The prevailing hypothesis among MDSC biologists today suggests 
that generation of MDSCs in pathology occurs in two steps. First there is an 
expansion of the immature myeloid cell (IMC) population, subsequently followed 
by an "activation" signal leading to their acquisition of suppressive characteristics. 
This model is based upon the emergency and extramedullary myelopoiesis which 
is a result of the non-resolving or chronic inflammation induced by conditions such 
as cancer, sepsis, or autoimmunity [93, 119]. The prolonged inflammatory 
pressures at these sites promotes the migration of IMCs from the bone marrow to 
replace exhausted or dead myeloid populations at the origin of the insult. Additional 
expansion of this IMC population can occur in the spleen in response to secondary 
tumor-derived signals. It's this secondary signal, usually in the form of pro-
inflammatory cytokines (IFNγ), Th2-associated cytokines (IL-4 or IL-13), or TLR 
ligands (DAMPs), that causes the cells to develop suppressive functional abilities 
[99].  
An alternative hypothesis concerns the nature of the secondary, "activation" 
signal. In this model abnormally prolonged inflammation still induces emergency 
and extramedullary myelopoiesis, mobilizing and expanding IMCs. In this case 
however, the secondary signal arrests any further maturation of these cells [120-
123]. Here it is assumed that the suppressive activities of MDSCs are actually an 
inherent quality possessed by all IMCs which differentiate into macrophages, DCs, 
and neutrophils so quickly under steady-state conditions that these abilities are of 
little consequence.  
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The exact "expansion" and "activation" signals that lead to the accumulation 
of MDSCs vary greatly depending upon the condition and even differ among tumor 
models. These cells are highly susceptible to signals in their microenvironment and 
will attune their gene expression and function in response [101]. In practice this 
means that MDSCs isolated from two different kinds of tumors may have starkly 
different transcriptional profiles, making it difficult to accurately identify a signature 
“MDSC-inducing” signaling pathway. There are some candidate pathways and 
transcription factors however that have been linked to their myeloid suppressor 
phenotype (Figure 1.6). STAT3 activation is found almost universally within any 
MDSC population being characterized. IL-1β, IL-6, IL-10, GM-CSF, and G-CSF 
produced in the TME have all been associated with inducing STAT3-mediated 
transcription of Nox2 and Arg1, both of which regulate ROS-based immune 
suppression or the expansion of MDSCs at the tumor site [107]. IL-1β and IFNγ-
mediated signaling through STAT1 in addition to IL-4 and IL-13-mediated 
activation of STAT6 also promote MDSC immunosuppressive activity by 
upregulating Nos2, Arg1, and Nox2 expression. STAT-dependent gene 
transcription also contributes to immature myeloid cell migration from the bone 
marrow, MDSC differentiation, and their accumulation at the tissue site via Bcl2l1 
and S100a8/9 expression induced by GM-CSF signaling through STAT3 and 
STAT5 [124]. 
Common among many MDSC researchers who subscribe to the classic 
"two-signal" model, is a steadfast belief that MDSCs arise from an abnormal 
response to pathologically prolonged or non-resolving inflammation. In other 
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words, there is an inherent defect that has inappropriately sustained a pro-
inflammatory response and it's only under these conditions that MDSCs develop 
[97, 100]. Central to this is the assumption that MDSCs are fundamentally distinct 
from other immune cells, such as TReg and “M2” macrophages, that accumulate 
during the resolution phase of a normal immune response to promote wound 
healing and prevent further inflammation-derived tissue damage.  
There is some evidence that this way of thinking about MDSCs may not be 
quite as accurate as it was once considered to be. For instance, MDSCs have 
recently been shown to be essential for the maintenance of maternal-fetal 
tolerance. If MDSCs were generated by a defective immune response, then they 
would not be so closely associated with normal, successful pregnancies [90, 97]. 
MDSC recruitment during sepsis may provide additional evidence for this. These 
cells may impair bacteria-clearing immune responses at later time points, but their 
presence in early stages of septicemia prevents the detrimental tissue damage 
caused by the extreme inflammatory responses this condition elicits [93, 125]. With 
this in mind, some researchers have begun reexamining the nature of this original 
“two-signal” model with a few even rethinking what kinds of cells should or should 
not be considered MDSCs [93]. As Millrud, Bergenfelz [93] stated in their 2016 
review On the origin of myeloid-derived suppressor cells, “An important issue 
concerning MDSC generation to remember is that tumors do not invent new 
biology, they highjack existing mechanisms."  
Along these lines, recent studies on the nature of neutrophils have shown 
that, once activated, these cells can live much longer than we originally thought 
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and can develop either a pro- or anti-inflammatory phenotype based upon their 
surroundings. Initially these cells were separated from PMN-MDSCs using a 
density gradient since they were significantly more granular [126]. New evidence 
indicates however, that degranulated neutrophils are less dense and settle at a 
similar level as PMN-MDSCs following density centrifugation. This has led some 
researchers to hypothesize that a portion of the heterogeneous subset we classify 
as PMN-MDSCs, may actually be degranulated, immunomodulatory tumor-
associated neutrophils [100].  
As for the generation of M-MDSCs I prefer the model proposed by Millrud, 
et al. (2016) in the review quoted above. Like the classic hypothesis, theirs also 
consists of two signals, however instead of the "expansion" and "activation" of 
IMCs, they propose a model whereby monocytes are "recruited" and 
"reprogrammed". Damage or pathogen associated molecules trigger toll-like 
receptors on the surface of monocytes, recruiting these cells out of circulation. 
Once in the tissue or tumor site, these cells continue to encounter TLR agonists in 
addition to immunomodulatory signals such as IL-10. This combination of pro- and 
anti-inflammatory stimuli “reprograms” the monocyte, causing it to acquire immune 
suppressive functions [93]. The “recruit and reprogram” model is particularly 
appealing as it places M-MDSCs on a similar level as any other cell type that gets 
reprogrammed by tumor-derived signals. In either case, it is becoming increasingly 
clear with each new non-cancer-centric MDSC study that it is time to reassess not 
only our model of how MDSCs are generated, but also our one dimensional, 
pathology-oriented idea of these complicated cells. 
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Figure 1.6: Candidate signaling cascades contributing to MDSC 
accumulation and suppressive phenotype. The plasticity of MDSCs makes it 
difficult to precisely define a single “MDSC-inducing” signaling profile, there are 
some however that have been linked with various aspects of MDSC biology. 
DAMPs: danger-associated molecular patterns. 
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MDSCs in Healthy Tissues 
Our understanding of MDSC biology has greatly expanded since they were 
first described almost 20 years ago. Despite the growing list of conditions in which 
MDSCs play a beneficial role, the majority of studies on their biology is still done 
within the realm of cancer.  Furthermore, the assumption that these cells only arise 
from pathologically induced abnormal maturation still permeates the field. CD11b+ 
Gr1+ cells found in healthy tissues are often dismissively classified as immature 
myeloid cells without further functional studies since it’s assumed that the 
immunosuppressive activity of those cells only arises as a consequence of 
inappropriately prolonged emergency myelopoiesis or chronic inflammation. 
The endurance of this belief may be strongly linked to their original 
discovery in the tumor microenvironment and the profound role they play in priming 
it for optimum immune evasion. If these cells had been discovered under different 
conditions, investigations may not have been so narrowly focused. For instance, 
the immunosuppressive nature of tumor-associated macrophages is considered a 
pathological consequence of the tumor microenvironment on these cells, but 
macrophages in and of themselves are not associated solely with disease. Even 
immunosuppressive "M2-like” macrophages are seen as physiologically normal in 
steady-state conditions. Testing the functional activity of macrophages isolated 
from healthy tissues is important and, for the most part, seen as a necessary step 
in characterizing a novel population. 
The explosion of CD11b+ Gr1+ cells under chronic inflammatory pressures 
should also not be used to justify our disregard for the effector functions of these 
cells in steady state. Knowing that T cells clonally expand following antigen 
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recognition does not prevent CD3+ CD4+ cells from being recognized as bona fide 
T cells when they're isolated from healthy tissues. 
Molecular signals within the surrounding tissue have a profound impact on 
macrophage and T cell differentiation and functional phenotype. It’s thought that a 
similar dynamic occurs with MDSCs within the tumor microenvironment, as 
MDSCs isolated from different types of tumors often exhibit different patterns of 
gene expression and use different mechanisms to suppress inflammatory 
responses [102]. Furthermore, several studies over the last few years have 
revealed more and more non-tumor associated instances that give rise to MDSCs 
[90] [90-92]. In autoimmune diseases such as rheumatoid arthritis, MDSCs 
suppress inflammatory T cell responses and drive TReg induction via their 
production of IL-10 [127]. MDSCs have also been identified outside the realm of 
pathology altogether. Although the situations described thus far represent 
physiologically normal, perturbations of tissue homeostasis such as becoming 
pregnant or being recently born. In each case MDSCs play a protective role against 
fetus-directed and overactive immune responses respectively [90, 128]. To me, 
this all indicates that the suppressive MDSC phenotype develops more from the 
cues an immature myeloid cell encounters within a particular microenvironment 
than as a consequence of the pathology itself. Taken one step further, this implies 
that any tissue containing the appropriate combination of molecular signals could 
give rise to its own population of MDSCs. 
As the list of MDSC-inducing conditions grows and begins to include 
physiologically normal situations like pregnancy [90], MDSC biologists need to 
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reexamine their perceptions of these cells. Perhaps even consider the possibility 
that they are alternatively activated monocytes and neutrophils involved in 
mediating tissue homeostasis and repair, just like their alternatively activated 
macrophage counterparts.  
The MDSC-inducing Potential of Healthy Adipose Tissue 
Both leptin knockout and high-fat diet-fed mice develop chronic, low-grade 
adipose tissue inflammation, which leads to the accumulations of MDSCs [129]. 
Similar to what is seen in autoimmune-induced inflammation these cells play a 
protective role in the tissue by offsetting the metabolic dysfunction associated with 
obesity [129, 130]. Intriguingly the studies that first identified these cells in inflamed 
adipose also describe a population of CD11b+ Gr1+ cells in the adipose of their 
normal diet-fed, negative control mice. Unfortunately, the immunomodulatory 
functions of these cells were never tested, as it was assumed that cells with these 
surface markers did not develop immunosuppressive capabilities in the absence 
of pathological pressures. However, the microenvironments of tumors and healthy 
adipose tissue share many common elements as they both have a propensity for 
employing a network of cellular and molecular players to promote and sustain 
robust anti-inflammatory conditions. Surprisingly, many of the shared elements of 
this network are involved in the recruitment of MDSCs by tumors. Therefore, if we 
assume that an MDSC acquires its immunomodulatory nature as a consequence 
of signals from its surroundings and not pathology itself, then it’s likely that the 
CD11b+ Gr1+ cells in the adipose of their negative controls would have inhibited 
31 
activated T cell responses. Table 1.2 highlights some of the key similarities 
between tumors and healthy adipose tissue. 
On a macro level, both tumors and adipose are dynamic tissues where both 
pro- and anti-inflammatory stimuli are found. The coexistence of these 
diametrically opposed signaling molecules are essential elements in the “Recruit 
and Reprogram” model of MDSC generation [93]. From a cell network point of 
view, tumor-associated macrophages (TAMs) are one of the driving forces behind 
MDSC recruitment and retention at the tumor site. TAMs provide IL-10 which 
reprograms recruited monocytes into suppressive MDSCs. Additionally, IL-10 
produced by MDSCs promotes the “M2” phenotype of TAMs, establishing a 
mutually beneficial feedback loop. This allows for more MDSCs to accumulate and 
strengthen the immunosuppressive nature of TAMs. In healthy adipose tissue, the 
similarly “M2” skewed tissue-resident macrophage (ATM) population produces IL-
10 [20, 131, 132] which is a necessary component of the anti-inflammatory AT 
environment. 
T cells play a critical role in creating the optimum niche for MDSCs in the 
tumor microenvironment. For instance, IFNγ and TNFα produced by tumor-
infiltrating effector T cells provide the chronic myelopoiesis and the eventual 
recruitment of immature myeloid cells (IMCs) to the tumor site [133]. Meanwhile, 
induced regulatory T cells prime the microenvironment with IL-10 and TGFβ 
contributing to the pool of anti-inflammatory cytokines that can reprogram IMCs 
into MDSCs [134, 135]. Both effector memory and regulatory T cells are present 
in healthy adipose tissue.  
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Some of the other players in the adipose immune cell network such as ILC-
2s and NKT cells are also involved in establishing the immunosuppressive 
conditions in the tumor microenvironment. In both tumors and adipose these cells 
promote “M2” polarization of the resident macrophage populations via IL-13 
production [136-138]. This cytokine can also contribute to the suppressive 
phenotype of MDSCs. Collectively, these similarities with the tumor 
microenvironment make healthy adipose tissue a likely niche for MDSCs to 
accumulate.  
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CHAPTER 2: METHODS & MATERIALS 
Animals 
C57BL/6J mice were purchased from Jackson Laboratory [Bar Harbor, ME, 
USA] or bred in-house. Unless stated otherwise all reported findings were from 10-
26-week-old male mice. All animal studies were performed under protocols 
approved by the University of Louisville Institutional Animal Care and Use 
Committee and complied with the National Institutes of Health Guidelines for the 
Care and Use of Laboratory Animals.  
Stromal Vascular Fraction Isolation 
Perigonadal fat pads (epididymal or uterine horn) were harvested from 5-10 
mice and collected in sterile 0.1% BSA solution. In a sterile petri dish, the pooled 
adipose tissue was manually homogenized with scissors. 1mL of Digestion Buffer 
(2mg Collagenase [Worthington Biochemical Corporation; Lakewood, NJ, USA], 
1mg DNase [Sigma-Aldrich; St. Louis, MO, USA], 1mL 0.1% BSA) per milliliter 
adipose tissue was added to the homogenized tissue. The total solution (adipose 
+ digestion buffer) was collected in a 50mL conical vial containing a stir bar and 
digested at 37° C in an Envirogenie (37.5 rpm) for 35 minutes. Following digestion, 
the contents of the tube were transferred to fresh 15mL conical vials and 
centrifuged for 4 minutes at 550 x g. The supernatant was discarded; the cell pellet 
was resuspended in 0.1% BSA; and centrifuged once again for 3 minutes at 400 x 
g. Cell were resuspended in 0.1% BSA and passed through a 20μm filter.
Some experiments required SVF cells to be isolated from individual mice, 
in order to fully appreciate the variability that exists in terms of adipose stromal cell 
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make-up. For these isolations, the epididymal fat pads were collected from each 
animal in 3mL 0.1% BSA and kept at 4° C until they were processed. The tissue 
was then transferred to a fresh 5mL tube where it was manually homogenized with 
scissors. One volume of Digestion Buffer was added, and the tubes were 
incubated at 37° C in a tube rotator for 35 minutes. When processing multiple 
samples at once, homogenization and incubation was staggered to ensure even 
digestion times for each sample. Following digestion, cold 0.1% BSA was added 
to each tube. Samples were centrifuged at 550 x g for 4 minutes. Supernatants 
were discarded, and the pellet was transferred to a new 5mL tube. After 
resuspension, the cells were centrifuged once more at 400 x g for 3 minutes. Fresh 
0.1% BSA was added to the washed cells which were then filtered through a 20μm 
filter cup [pluriSelect Life Science; Leipzig, Germany]. To ensure maximum cell 
yield, the tube was rinsed twice and the filter once with 5mL 0.1% BSA. This 
individual cell isolation protocol produced cell yields and population distributions 
that were comparable to our pooled SVF isolation protocol. 
Flow Cytometry Staining for Analysis 
Adipose stromal cells and splenocytes were incubated in Fc block for 10 
minutes in the dark, at room temperature. Cells were stained with appropriate 
monoclonal antibodies for 20-30 minutes at room temperature. Table 2.1 contains 
the antibodies included in each staining panel used in this study. Intracellular 
staining for Foxp3 and Ki-67 was performed using Foxp3/Transcription Factor 
Staining Kits [eBioscience; San Diego, CA, USA] according to the manufacturer’s 
instructions. Data was collected on an LSR II cytometer [BD Biosciences; Franklin 
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Lakes, NJ, USA] and analyzed with FlowJo software [Tree Star; Ashland, OR, 
USA].  Compensation beads [BD Biosciences] were used for data collection, but 
compensation was manually adjusted during analysis to account for the 
autofluorescent nature of adipose stromal cells. 
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Table 2.1: List of Antibodies Used in Flow Cytometry Panels. 
38 
Cell Sorting 
For sorting adipose-derived MDSCs (aMDSCs), total adipose stromal cells 
were stained with CD11b APC [Miltenyi Biotec; San Diego, CA, USA], Ly6C FITC 
[VWR; Radnor, PA, USA], and Ly6G PE-Cy7 [VWR]. CD11bHi Ly6CHi Ly6G- 
SSCLow cells were then sorted by the University of Louisville Microbiology and 
Immunology Flow Cytometry Core Facility on a FACS Aria III [BD Biosciences] 
(Figure 2.1 a). We found that stresses inherent to the sorting process negatively 
impacted the suppressive phenotype of FACS-isolated MDSCs. However, if the 
cells were allowed to recover for 4-5 hours at 4°C they regained their 
immunomodulatory functionality [139, 140] (Figure 2.2). 
For sorting adipose tissue T cells and macrophages, total adipose stromal 
cells were stained with CD11b PE [Miltenyi Biotec], Ly6C FITC [VWR], CD4 APC-
Cy7 [VWR], MHC-II PE-Cy7 [VWR], and CD301 AlexaFluor647 [Bio-Rad; 
Hercules, CA, USA]. Both CD11b+ Ly6C+ CD301+ MHC-II+ adipose macrophages 
(Figure 2.1 a) and CD11b- CD4+ adipose T cells were collected (Figure 2.1 b).  
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Figure 2.1: Cell sorting strategies for FACS isolation of SVF subpopulations. 
(a) MDSC & adipose macrophage sort strategy (b) Adipose tissue T cell sort 
strategy. 
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Figure 2.2: FACS isolated aMDSCs require a brief rest period before use in 
proliferation assays. Sorted aMDSCs were either immediately resuspended in 
RPMI and plated (non-rested) or left in sort buffer at 4° C for 3 hours before being 
resuspended in media and plated (rested). aMDSCs were co-cultured with 
αCD3/αCD28 activated MACS-enriched T cells. After five days T cell proliferation 
was assessed by measuring Abs at 450nm. Abs values within each experiment 
were normalized to create a PI relative to the mean Abs of αCD3/αCD28-
stimulated MACS-enriched T cells. Finally, each co-culture was then analyzed via 
flow cytometry to determine what proportion of the remaining live cells was made 
up of aMDSCs. (a) The frequency of remaining aMDSCs in each co-culture versus 
activated T cell proliferation (Proliferation Index). Each circle represents an 
individual well. (b) αCD3/αCD28-stimulated T cell proliferation following five-day 
co-culture with non-rested (Blue) or rested (Pink) aMDSCs.  
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T Cell Proliferation/Suppression Assays 
Adipose stromal cells were processed and isolated as described from 10, 
16 – 20-week old, male mice. Cells were then stained and sorted as described 
above. While the sorted cells were resting, spleens from 2-3 mice were manually 
disrupted and passed through a 100 μm cell strainer. The single cell suspension 
was washed twice with sterile HBSS and filtered a final time through a 70 μm cell 
strainer. Total splenocytes were counted, then enriched for T cells using a negative 
selection magnetic bead separation kit [Miltenyi Biotec] according to the 
manufacturer’s instructions. MACS-enriched T cells and sorted adipose-derived 
CD11bHi Ly6CHi Ly6G- SSCLow cells were resuspended in media [RPMI 1640 
supplemented with 10% FBS, 2-Mercaptoethanol, Pen/Strep, Fungizone, and 
EDTA] and plated at a 1:1 ratio in a 96-well culture plate. The final culture volume 
in each well was 100uL. Some wells were coated with 1ug/mL αCD3 and 3ug/mL 
αCD28 to activate the T cells. Each culture condition was performed in triplicate.  
Due to the small number of CD11bHi Ly6CHi Ly6G- cells obtained from each 
sort, the use of traditional flow cytometry or radiation-based proliferation assays 
was not feasible, as the low cell numbers made it difficult to reliably obtain 
repeatable results with these standard methods (See detailed explanation under 
Chapter 3: Experimental Challenges & Model Development). As an alternative, 
T cell proliferation was assessed, after 5 days, using a colorimetric MTT assay, 
according to the manufacturer’s instructions [TetraZ Cell Proliferation Kit; 
BioLegend; San Diego, CA, USA] (Figure 2.3). Suppression of T cell proliferation 
was determined by establishing a “Proliferation Index” (PI) where the absorbance 
value obtained from each co-cultured well was divided by the mean absorbance of 
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activated T cells or splenocytes alone. Mean PI values were calculated for each 
co-culture condition. Values greater than 1 indicated an increase in T cell 
proliferation, while PI values significantly less than 1 indicated that T cell 
proliferation had been suppressed. To further confirm that the differences in 
absorbance values between co-culture conditions were due to differences in T cell 
proliferation and not the result of variations in metabolic activity, we stained the 
cells with CD4 and CD8 following the final MTT measurement, then determined 
the absolute number of T cells in each well using flow cytometry using Accucount 
Beads [Spherotech; Lake Forest, IL, USA]. 
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Figure 2.3: Schematic of TetraZ-based MTT assay workflow. Naïve 
splenocytes or MACS-enriched T cells are cultured by themselves, activated with 
plate-bound αCD3/αCD28, or activated and co-cultured at a 1:1 ratio with either 
Full SVF, aMDSC-depleted SVF (ΔaMDSCs), or sorted aMDSCs. After 3 – 5 days, 
10μL of TetraZ reagent is added to each well and returned to the incubator for 4 – 
6 hours. After incubation, absorbance is measured at 450nm. 
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RNA Isolation, RT-PCR & qPCR 
RNA for this study was isolated with the RNeasy Mini or Micro Kits [Qiagen; 
Germantown, MD, USA] depending on the size of the sample. Prior to RNA 
isolation, cells and tissue lysates were homogenized with Qiashredder columns 
[Qiagen]. Lysates from whole adipose tissue were collected via Qiazol [Qiagen] 
and chloroform extraction. They were homogenized with the Qiashredder columns 
before RNA purification with the RNeasy Mini Kit [Qiagen]. cDNA synthesis was 
performed using SuperScript IV VILO with ezDNase [Thermo Fisher Scientific; 
Waltham, MA, USA]. SYBR Select Master Mix [Thermo Fisher Scientific] was used 
to perform qPCR on a StepOne Plus thermocycler [Applied Biosystems; Foster 
City, CA, USA]. In some cases, amplified DNA products were visualized by 
agarose gel separation. IL-2 amplification was performed with the Mm_Il2_1_SG 
QuantiTect Primer Assay kit [Qiagen] while all other mouse primers were designed 
and purchased through IDT [Integrated DNA Technologies; Coralville, Iowa, USA]. 
Primer sequences are listed in Table 2.2. 
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Table 2.2: List of qRT-PCR primers. 
Target Gene Forward (5’  3’) Reverse (5’  3’)





Tbp CTACCGTGAATCTTGGCTGTAA GTTGTCCGTGGCTCTCTTATT 
Tgfb1 GGACTCTCCACCTGCAAGAC GACTGGCGAGCCTTAGTTTG
Tnfa GAGAAAGTCAACCTCCTCTCTG GAAGACTCCTCCCAGGTATATG 
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In Vivo MDSC Depletion 
16-week-old male mice were injected subcutaneously with 15 μg g-1 of 
purified Gr-1 (αGr1) antibody [Clone: RB6-8C5] or Rat IgG2b isotype control 
[Clone: LTF-2] [BioXCell; West Lebanon, NH, USA], every 3-4 days throughout the 
duration of the experiment. Animals were weighed at each injection to monitor for 
any negative metabolic effects of the treatment. Both epididymal fat pads were 
collected at the end of the experiment (no more than two days after the final 
injection). Spleens were collected from each mouse to verify successfully MDSC 
depletion and check for any other systemic effects induced by the treatment. 
ELISAs 
T cell proliferation assays were set up as described above. After two days, 
50 – 100 μL of supernatant was collected from each well and stored at -80° C in a 
separate 96-well plate. A matching volume of media was added back to the co-
cultures and the plate was returned to the incubator for the duration of the 
experiment. Later, frozen supernatants from multiple experiments were thawed at 
room temperature and centrifuged to remove any suspended particulate matter. 
Cytokine specific ELISA kits were then used to test the supernatants for the 
presence of either IL-10 [Mouse IL-10 Quantikine ELISA Kit; R&D Systems; 
Minneapolis, MN, USA] or TGFβ [Mouse/Rat/Porcine/Canine TGF-β 1 Quantikine 
ELISA Kit; R&D Systems] according to the manufacturer’s instructions.  
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Statistical Analysis 
Statistical analyses were performed with SigmaPlot 14 [Systat Sofware, Inc; 
San Jose, CA, USA]. Absorbance values obtained from the T cell suppression 
assays were analyzed using a one-way ANOVA followed by Holm-Sidak post hoc 
tests. All comparisons between untreated and αGr1-treated animals were 
analyzed using a Student’s unpaired t-test. Data are presented as means ± SEM 
unless otherwise indicated. Correlation strength was determined by calculating the 
Pearson’s coefficient, where R values of 0.7 – 1.0 were considered “Strong” 
correlations and values between 0.5 – 0.7 were considered “Moderate”. 
Significance of these correlations were determined using these R values. For all 
statistical analyses, the significance level was set at P ≤ 0.05. 
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CHAPTER 3: EXPERIMENTAL CHALLENGES & MODEL 
DEVELOPMENT 
Several aspects of this project presented some unique experimental 
challenges that necessitated the adaptation and development of new models. 
These challenges fell into one of two general categories: culturing ultra low 
numbers of cells or working with a complex heterogeneous peripheral tissue. 
T Cell Proliferation Assays: Adaptations for working with small cell 
populations. 
Initially we decided to use CFSE dilution to assess T cell proliferation in our 
mixed cell co-cultures. For these assays splenocytes were processed as described 
above, then resuspended to 40×106 cells/mL. The CFSE stain was reconstituted 
at room temperature according to the manufacturer’s instructions. A 5μM working 
solution was made up by adding 5μL of the stock CFSE to 10mL sterile HBSS. 1 
volume of this solution was added to the splenocytes (i.e. 2mL of splenocytes at 
40×106 cells/mL were stained with 2mL CFSE working solution). Cells were 
incubated for 5 minutes in a 37°C water bath, removed promptly and incubated 
another 5 minutes at room temperature, protected from light. The reaction was 
quenched with enough HBSS-2% FBS to fill the tube, then mixed thoroughly by 
pipetting. Cells were centrifuged at 350 x g for 5 minutes, washed with HBSS-2% 
FBS, and spun once more with the same settings. After the final wash, cells were 
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resuspended in 5mL RPMI-10% FBS and counted using the nucleocounter. The 
splenocytes were then analyzed on the flow cytometer to check if the cells had 
been sufficiently stained. The percentage of CD4+ and CD8+ splenocytes was also 
determined at this time. This allowed us to properly resuspend the splenocytes 
according to number T cells so that they could be co-cultured with the sorted 
aMDSCs at a 1:1 ratio of T cells to aMDSCs. 
After 5 days, each co-cultured well was stained with CD4 and CD8 so that 
CFSE dilution could be examined specifically in the T cells. Cells were stained in 
the 96 well plate, resuspended in 200μL of wash buffer, and transferred to a 
microtube for analysis. The wells were rinsed once more with 200µL of wash buffer 
which was also transferred to the corresponding microtube. 
Our pilot experiments using this protocol had mixed success due to 
inconsistent T cell activation. Without this positive control, we were unable to 
determine whether or not our adipose-derived cells were affecting T cell 
proliferation. After verifying our reagents, we concluded that the concentration of 
T cells in each well was too low to establish a sufficiently robust IL-2 and IL-4-
driven autocrine feedback loop to sustain a proliferative T cell response. Ultimately 
it was this observation that motivated our search for an alternate method to detect 
changes in T cell proliferation that might have increased sensitivity to more subtle 
changes in T cell numbers. We also worked to optimize our culture system to 
ensure consistent T cell activation with each experiment. 
Since a demonstrated ability to suppress inflammatory T cell responses is 
the “gold standard” for MDSC characterization we needed to optimize our culture 
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system to ensure consistent T cell activation with each experiment. To this end we 
tested various combinations of soluble and plate-bound αCD3/αCD28 antibodies 
at different concentrations. Eventually, we developed a conditional culture system 
that was based upon the final number of cells in each well (Table 3.1). 
Table 3.1: Conditional T Cell Activation Algorithm for Co-cultures. 
Once we had a system in place to consistently induce T cell proliferation, 
we turned to the problem of measuring the potential suppressive activity of the 
adipose-derived cells. As the pilot experiments had demonstrated, cytometry-
based methods were theoretically possible. In practice however, this turned out to 
be tedious and extremely time-consuming. More importantly CFSE-dilution was 
not nearly as sensitive of a detection method when it was scaled down to the level 
of 6000 T cells per well. An issue that was further compounded by the fact that 
these cells were being co-cultured with adipose SVF, which notoriously auto-
fluoresces in the FITC channel (the same channel used to detect CFSE signal). 
This desire to produce consistently reliable and unambiguous results motivated 
our search for alternate ways to assess aMDSC-mediated changes in T cell 
proliferation. 
Eventually we landed on a new form of MTT assay, which preserved cellular 
viability by producing a soluble dye instead of an insoluble precipitate. This left us 
Total Cell # / Well 





5000 – 10000 3 μg/mL 3 μg/mL
> 10000 1 μg/mL 3 μg/mL 
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the option to further analyze the co-cultures using flow cytometry or even to assess 
T cell activity over time as long as the cells were washed and resuspended in fresh 
media afterwards. The major advantage of this type of assay however was its 
sensitivity, as it could provide an accurate assessment of cell number in cultures 
with as few as 5000 cells per well. 
Choosing this method did require a few compromises on our part. For 
instance, in cytometry-based systems you have the option to stain for cell-specific 
markers which allows for the identification of the exact cell populations that are 
proliferating. Since the MTT assay format, at its core, is a semi-quantitative, 
relative assessment of cell number in each well and is based on their metabolic 
activity it is impossible to know what cells are contributing to the differences 
between conditions. This meant that we could not assume that absorbance value 
differences between the positive controls and the experimental conditions were 
solely due to changes in T cell proliferation. However, we determined that the loss 
of this specificity was acceptable as the more traditional H3-thymidine incorporation 
method suffers from a similar issue in that all proliferating cells are radio-labeled, 
not just T cells. 
The MTT assay format we chose was a water-soluble tetrazolium salt 
(WST) assay and is based on the activity of cellular dehydrogenases. These 
essential enzymes are involved in oxidative phosphorylation and use the potential 
energy of electrons to actively transport hydrogen ions into the intermembrane 
space of mitochondria. The electrons released during the oxidation reactions are 
then transferred to an electron mediator such as ubiquinone. This is the step that 
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the WST assay takes advantage of. The reagent is added directly to the co-culture 
supernatant and contains its own water-soluble electron mediator. This molecule 
scavenges the electrons that typically reduce ubiquinone and transports them 
extracellularly where they can be used to convert a tetrazolium salt into formazan, 
a water-soluble dye. As cellular dehydrogenase activity increases, more electrons 
are released, resulting in an increased production of formazan. Ultimately, this 
changes the color of the culture supernatant from light yellow to orange, which is 
then quantified by measuring light absorbance at 450nm. The higher the 
absorbance value is, the more metabolic activity that is going on in the well, and 
the more cells in that particular culture condition. 
Even with three successful iterations of this MTT-based assay under our 
belts, we were still concerned about the fact that at its core MTT assays rely on 
the assumption that all the cells within a given co-culture are metabolizing at a 
comparable rate. Since we had improved the reliability of our small-scale T cell 
activation protocol, we decided to try the flow cytometry-based proliferation assays 
one again in order to verify that the absorbance changes we observed in the MTT 
assays did result from a true decrease in T cell proliferation. Cell number titrations 
revealed that we were able to reliably measure CFSE dilution with as few as 5000 
MACS-enriched T cells. Additionally, these titrations indicated that Day 3 of the 
culture would be the optimal time to collect proliferation data as the CFSE dye was 
completely diluted and undetectable by Day 4 (Figure 3.1). All in all, three T cell 
suppression assays were performed according to these parameters. None of them 
however showed that adipose-derived MDSCs (aMDSCs) had any of the 
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suppressive activity that was observed in the previous MTT assays (Figure 3.2 a). 
After comparing the set-up of the MTT and CESE assays we determined that there 
were two major differences that could have resulted in these discrepancies 
between the sets of experiments: the kinds of responder cells we used and the 
length of time the cells were co-cultured. 
The original MTT assays used splenocytes while MACS-enriched T cells 
were used for the CFSE set. Given the diverse array of effector mechanisms at 
their disposal, it was possible that MDSCs were promoting M2 polarization in 
splenic macrophages which were then responsible for the observed reduction in T 
cell proliferation. To test for this, we compared aMDSC-mediated suppression 
between MACS-enriched T cells and splenocytes. Once again, we did not see any 
immunomodulatory activity in the co-cultures with MACS-enriched T cells. 
Surprisingly, suppressive activity was absent from the splenocyte co-cultures as 
well (Figure 3.2 b). This implicated the time that these cells spent in co-culture as 
the source of these discrepancies. 
The CFSE-based proliferation assays as well as the assay comparing 
splenocytes and purified T cells were all analyzed on culture Day 3, while the co-
cultures in the original set of MTT experiments had been allowed to run through 
Day 5. To this end, two sets of MDSC co-cultures were set up simultaneously with 
proliferation being assessed on either Day 3 or 5. We had to return to the MTT 
format for those experiments as CFSE would be completely diluted by Day 5 
(Figure 3.2 c). Using these parameters, we observed a striking difference between 
days 3 and 5 in terms of MDSC-mediated suppression of T cell proliferation. As 
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with previous experiments there was little to no suppressive activity on culture Day 
3 regardless of whether MDSCs were co-cultured with splenocytes or MACS-
enriched T cells. By Day 5 however, the PI in MDSC co-cultures was significantly 
less than one indicating that suppression had occurred (Figure 3.2 c). As further 
verification of these results, T cells were counted in each well after absorbance 
measurements were taken. Here we found that MDSC co-cultures on Day 5 had 
significantly fewer T cells than the positive controls, while there wasn't a difference 
between the two culture conditions on Day 3. Besides providing additional 
optimization parameters for these suppression assays, these troubleshooting 
experiments gave us valuable insight into aMDSC biology. First, whatever effector 
mechanism aMDSCs are using does not prevent the initial activation and 
subsequent proliferation of naïve T cells. Instead it appears to stop proliferation 
over time, once it has already started. Second, aMDSC-mediated immune 
modulation can directly affect T cell proliferation without the need for an 
intermediary cell type such as M2 macrophages (Figure 3.2 d). 
As the MDSC-mediated suppression could only be detected after 5 days, 
we were once again faced with the problem of non-specificity. The MTT format is 
more often used to determine the cytotoxicity of a specific treatment or drug. 
Traditionally, these cell viability assays use a single cell line making it easy to 
assume that changes are due to the experimental conditions themselves and not 
different cell types behaving differently. However, for our suppression assays, 
there would be two (aMDSCs and MACS-enriched T cells) or more (in the case of 
splenocytes) different cell types in each co-culture. This heterogeneity meant that 
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the results could not be taken at face value, as the metabolic activity of our effector 
cells could inadvertently be influenced by the presence of activated T cells. To 
account for this, we developed a secondary method to verify the final number of T 
cells in each culture condition. On day 5, following the final MTT absorbance 
measurement, cells were washed and stained with CD4 and CD8 antibodies. Then 
the entirety of each individual well was collected at the cytometer in order to 
calculate the final number of T cells in each co-culture. Finally, we correlated the 
absorbance values from the MTT assay with the absolute number of CD4+ T cell 
numbers in each well (Figure 4.4 e). This revealed that there was a strong 
correlation between these two values (R = 0.9978), confirming that this assay could 
be used to reliably measure both T cell proliferation and the suppressive potential 
of adipose-derived MDSCs in a heterogeneous mixture of cells.  
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Figure 3.1: CFSE can be used to measure the proliferation of as few as 2500 
MACS-enriched T cells. (a) Schematic of CFSE titration experimental design. (b) 
Histograms showing CFSE dilution profiles in αCD3/αCD28-stimulated CD4+ T 
cells after 3, 4, or 5 days. 
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Figure 3.2: MDSCs suppress αCD3/αCD28-stimulated proliferation of 
splenocytes and MACS-enriched T cells. (a) Naïve, CFSE-stained, MACS-
enriched T cells were activated with plate-bound αCD3/αCD28 and co-cultured 
with aMDSCs. After 3 days CD4+ T cell proliferation was assessed by measuring 
CFSE dilution with flow cytometry. Data is pooled from three independent 
experiments where each co-culture was performed in triplicate. (b) Naïve 
splenocytes or MACS-enriched T cells were activated with plate-bound 
αCD3/αCD28 and co-cultured with aMDSCs. After 3 days proliferation was 
assessed via MTT assay. Data derived from one experiment where each co-
culture condition was performed in triplicate. (c) αCD3/αCD28-stimulated 
splenocytes were co-cultured aMDSCs for three or five days. Proliferation was 
assessed at each time point via MTT assay. Data derived from one experiment 
where each co-culture condition was performed in triplicate. (d) Naïve splenocytes 
or MACS-enriched T cells were activated with plate-bound αCD3/αCD28 and co-
cultured with aMDSCs. Proliferation was assessed after five days via MTT assay. 
Data pooled from two independent experiments where each condition was 
performed in triplicate. 
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Accommodations for the Unique Nature of Adipose Stromal Cells 
Flow Cytometry Gating Strategies 
As this was the first time that anyone had specifically looked at the impact 
of αGr1 depletion on healthy adipose, we were uncertain as to what kinds of 
changes we could expect in terms of immune cell dynamics. We hypothesized that 
MDSC depletion in vivo would increase signs of overt inflammation in the tissue. 
However, we were unsure as to the exact ways in which this might manifest. We 
developed multi-color staining panels for flow cytometry to identify and 
characterize a broad range of cell types, classically associated with obesity-related 
AT inflammation. 
Some of the earliest charges that occur at the cellular level in obesity take 
place in the macrophage and T cell compartments [141, 142], so we chose to 
analyze each sample with two distinct staining panels that targeted some of the 
key phenotypic features of each of these cell types. The MDSC/Macrophage panel 
included some of the classic markers associated with the "M2" to "M1" phenotypic 
switch that occurs in the early stages of obesity [21, 29] (Figure 3.3 a). 
Occasionally, due to a shortage of the CD301 or Ly6G antibodies, an alternative 
gating strategy was used to define adipose tissue macrophages (Figure 3.3 b) and 
MDSCs (Figure 3.4 a). There was no difference between these two strategies in 
the final number of MDSCs found within the tissue (Figure 3.4 b). As for the panel 
designed to detect changes in T cell dynamics, we included markers indicative of 
T cell activation in case MDSC depletion elicited an inflammatory response similar 
to what is observed in obesity. This panel also included markers that could be used 
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to distinguish between various T cell subsets (i.e. regulatory, effector memory, and 
central memory T cells) which are sensitive to changes in the inflammatory state 
of AT [39] (Figure 3.5).  
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Figure 3.3: SVF Myeloid Cell Gating Strategy (a) Gating strategy used to 
characterize MDSCs and  adipose tissue-resident macrophages (ATMs) in AT SVF 
(b) Alternate ATM gating strategy used when CD301 was not present in staining 
panel (c) Cell markers and the fluorophores used to characterize myeloid cell 
populations in the spleens and AT SVF of C57Bl/6 mice. 
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Figure 3.4: Alternative MDSC Gating Strategy (a) Representative dot plots 
depicting the gating strategies used to quantify adipose-resident MDSCs based on 
the absence (Upper) or presence (Lower) of Ly6G and CD301 in the staining 
panel. The Ly6C vs Ly6G dot plot used in the “Ly6C Hi/Low” gating strategy was 
previously gated on the total CD45+ CD11b+ CD301- SVF cells. The CD11b vs 
Ly6C dot plot shown in the “Total MDSC” gating strategy was previously gated on 
CD45+ SVF cells. (b) Absolute number of MDSCs found in the SVF of untreated 
or αGr1-treated mice using either the “Total MDSC” (Blue) or “Ly6C Hi/Low” (Pink) 
gating strategies. The numbers shown for the “Hi/Low Gates” gating strategy were 
obtained by combining both M-MDSC and PMN-MDSC populations. Bars depict 
the mean of 11 untreated or 8 1-week αGr1-treated mice. Error bars depict SEM. 
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Figure 3.5: T Cell Phenotype & Activation State Gating Strategy. (a) Gating 
strategy used to examine T cell populations in AT SVF. (b) Cell markers and the 
fluorophores used to characterize myeloid cell populations in the spleens and AT 
SVF of C57Bl/6 mice. 
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Adjusting for Adipose Autofluorescence 
Once the panels were designed, the cells harvested and the data collected, 
we faced an additional challenge on top of our not knowing what specific cell types, 
if any, would change as a result of the αGr1 treatment. Adipose tissue is inherently 
autofluorescent [143]. This is a problem that plagues any researcher wanting to 
use fluorescence-based technology such as flow cytometry or confocal 
microscopy to tease apart the inner workings of this tissue. Multiple factors give 
adipose tissue and the SVF cells isolated from it their natural fluorescent qualities. 
One major factor is the dense extracellular matrix (ECM) that acts as the 
scaffolding that holds adipocytes in place and allows the stromal cells to travel 
throughout the tissue. A large portion of the ECM is composed of collagen fibers. 
The uniform, repetitive structure of this multi-unit protein predisposes it to vibrating 
at resonance frequencies [144, 145]. As a result, certain wavelengths of light cause 
these subunits to absorb enough energy that an election jumps up one energy 
level. As this energy dissipates, the election falls back to its original energy state 
consequently emitting a different wavelength of light [144].  
The extracellular matrix in adipose tissue is a major contributor to its natural 
fluorescence. This dense network of collagen and elastin fibers is an essential 
scaffold that holds adipocytes in place and allows stromal cells to travel throughout 
the tissue. Collagen fibrils are the primary structural proteins of any ECM and 
adipose is no exception [146, 147]. Each fibril is composed of three long α-helical 
subunits which twist together to form the final triple helical quaternary structure or 
this protein. The amino acid sequences are strikingly regular, exhibiting a fairly 
consistent pattern of Glycine–Proline–X, where X can be any amino acid [146]. 
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The identity of this third residue can influence the fluorescent nature of the final 
protein [144]. This feature is mostly observed with the inclusion of any of the 
aromatic amino acids: tryptophan, tyrosine, or phenylalanine. Structurally each of 
these molecules contains at least one benzene ring. Molecular ring structures, 
such as these, are uniquely able to retain their stability upon absorbing light 
energy. The absorbed photon excites electrons in the molecule causing them to 
jump to a higher energy state, but as this energy dissipates the elections fall back 
to their original energy level [148]. This leads to the emission of photons at a lower 
wavelength. Most collagen types contain a non-negligible number of tyrosine 
residues [146]. Collagen type VI, found in adipose [149], contains both tyrosine 
and phenylalanine residues, further enhancing the innate autofluorescence of the 
ECM in this tissue.  
In addition to aromatic amino acids within individual collagen fibrils, protein 
crosslinking can enhance a tissue’s autofluorescent qualities. For instance, a 
fluorescent compound known as pyridinoline forms as a byproduct of structural 
crosslinking between collagen and elastin fibrils during the formation and 
maturation of extracellular matrices in tendons and bones [145]. 
The final factor contributing to the auto fluorescence of our adipose SVF 
cells may actually result from the collagenase digestion itself. A recent study 
analyzed how collagenase I digestion altered the structural and fluorescent nature 
of collagen I [150]. They found that the innate fluorescence of this protein 
increased in a dose dependent manner following exposure to, collagenase I. 
Additionally, they determined that this was likely caused by an increase in the 
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exposure of tyrosine residues that have otherwise been shielded from direct light 
exposure by the triple helical structure of the intact protein. 
Since we know that the digestion process only breaks down the collagen 
fibers but does not  fully dissociate their connections to the cells themselves, it is 
very possible that the autofluorescence we observe in our SVF isolates stems, to 
some degree, from exposed tyrosine and phenylalanine residues on partially 
digested cell-associated collagen.  
Along with ECM-associated autofluorescence, adipose-resident 
macrophages also contributed to the spectral interference we encountered in our 
flow cytometric analysis of SVF samples. ATM autofluorescence is thought to be 
directly related to their functional activities within the tissue. For instance, one 
study found that macrophages with upregulated iNOS expression and activity were 
more fluorescent in the 488 channel than those expressing lower amounts of this 
enzyme [143]. They postulated that this increased fluorescence was likely caused 
by an increased concentration of the cofactors required for iNOS activity as 3 out 
of these 5 compounds have autofluorescent properties that emit light is the 488 
nm range. This same study also found that ATM autofluorescence increased 
proportionally with increased lipid uptake by these cells. They ascribed this lipid-
induced autofluorescence in ATMs to the high fat diet condition since they 
phagocytose the lipids released when overburdened adipocytes pyropoptose. A 
more recent study however found that ATMs in healthy mice also actively 
participate in lipid uptake and release, potentially acting as intermediaries between 
the adipocytes and systemic circulation [25]. 
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The natural fluorescent qualities of adipose tissue proved to be one of the 
most troublesome aspects of our flow cytometry experiments, primarily affecting 
our ability to accurate analyze our data by complicating the compensation process. 
We sought to reduce these issues as much as possible at every stage of the 
experiment. For instance, as we developed our staining panels, we tried to avoid 
using FITC or Alexa Fluor 488 conjugated antibodies since this is the major 
channel in which AT autofluoresces (Figure 3.6 a). Some of our panels had as 
many as 8 colors however, so this was not always possible. In these cases, the 
software generated compensation matrices were often thrown off by the inherent 
FITC positive aspects of our unstained controls. Additionally, some of the markers 
in our more exploratory panels were exclusionary or expressed at such low levels 
that using SVF cells for our single-color controls was not feasible. To ensure that 
we collected the best data possible and that we were able to accurately analyze 
these results we chose to use compensation beads.  
As an additional control we used the fluorescence minus one (FMO) 
technique to correct for the data spread that occurs when multiple colors are 
combined into the same staining panel. This allowed us to identify the true line 
between negative and positive cell populations in these multi-parameter 
experiments. 
Although each of these strategies helped to minimize the impact of 
autofluorescence on the data collection portion of each experiment, they were still 
only partially effective and the autofluorescent nature of adipose tissue and SVF 
cells was still measurable in most of our samples. Our primary means of correcting 
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this spectral overlap was by designing our own compensation matrices in the 
FlowJo analysis software (Figure 3.6 b). For each set of experiments, I would try 
to keep this matrix as consistent as possible between replicates. This was 
relatively easy to do as long as the data for each fluorophore was collected at the 
same PMT voltages as all the other replicates. Instead of building a new matrix 
from scratch or even having designing one based on my single-color compensation 
beads in FlowJo itself, I would often use the acquisition defined matrix as my 
starting point and adjust the overlap values as needed. 
I was able to determine what values required adjustment by looking at the 
dot plots of a fully stained sample and an unstained sample. I would then look at 
the plot for each fluorophore combination. Primarily I wanted to see that the 
displayed populations were distributed in a "natural", round shape as opposed to 
forming a diagonal line which is indicative of under compensation. I also adjusted 
overly compensated parameters which appeared as diagonal populations that 
extended beyond 0 for that fluorophore.  
The main concern when making compensation matrices by hand is overly 
adjusting the spectral overlap to the point that you inadvertently create false 
positive or negative cell populations. In my compensation process I paid particular 
attention to these potential artifacts and avoided definitively gating on populations 
that drastically shifted intensity with small charges in overlap values. Altogether by 
employing these strategies at each stage of the experiment we were successfully 
able to produce consistent and reliable data from multi-parametric flow cytometry 
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experiments despite the inherent autofluorescence of adipose resident 
macrophages and SVF cells in general. 
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Figure 3.6: Flow cytometry analysis of SVF requires manually adjusting 
spectral overlap values to account for the natural autofluorescence of AT. 
(a) Representative histograms comparing FITC or APC fluorescence in full SVF 
samples that were either left unstained (Pink) or stained for myeloid cell markers 
(Blue) (b) Representative dot plots depicting SVF samples that were either left 
unstained (Upper Row) or stained for T cell markers (Lower Row). SVF cells 
isolated from the same animal were used for both the unstained and stained 
samples. Data shown in the left column uses the compensation matrix calculated 
from the DIVA software and single-color stained compensation beads. The right-
hand column shows the same dot plots after correcting for autofluorescence. 
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CHAPTER 4: BONA FIDE MYELOID-DERIVED 
SUPPRESSOR CELLS IN HEALTHY ADIPOSE TISSUE
Previous work in our lab has examined the therapeutic value of the adipose 
tissue (AT) stromal/vascular cellular fraction (SVF) in improving vascular function 
[85, 151, 152]. In one study the SVF isolate lost many of its beneficial effects when 
the CD11b+ cells were depleted [85]. Further characterization of these 
therapeutically relevant CD11b+ cells found that approximately 45% of were also 
Gr1+. Similar populations of CD11b+ Gr1+ cells have been observed by others in 
the AT of healthy, control animals [129, 153], yet no detailed characterization of 
these cells has been performed to date. Given the immunomodulatory nature of 
the adipose tissue stromal cells in healthy mice we hypothesized that these 
CD11b+ Gr1+ cells were an adipose-resident population of immunosuppressive, 
myeloid-derived suppressor cells (MDSCs). 
There are CD11b+ Ly6CHi/Low Ly6G-/+ CD301- cells in healthy adipose tissue. 
In order to determine if these CD11b+ Gr1+ cells could be 
immunomodulatory, myeloid-derived suppressor cells (MDSCs), we first 
developed a detailed panel of surface markers to characterize the myeloid cell 
populations resident in healthy adipose tissue (AT). Ly6C and Ly6G were included 
as well as AT-resident macrophage markers F4/80, CD301, and MHC-II to 
differentiate neutrophils and polymorphonuclear-MDSCs (PMN-MDSCs) from 
adipose tissue macrophages, dendritic cells, and monocytic-MDSCs (M-MDSCs). 
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CD11b+ CD301- CD11c- Ly6CHi/Low Ly6G+/- MDSC-like cells made up 0.77 ± 0.07% 
of the SVF harvested from healthy AT. 85.73 ± 1.8% of these were Ly6CHi Ly6G- 
M-MDSC-like cells (0.63 ± 0.09% of the total SVF), while Ly6CLow Ly6G+ PMN-
MDSC-like cells accounted for the remaining 14.28 ± 1.76% of the CD11b+ CD301- 
CD11c- cells (0.12 ± 0.03% of the total SVF) (Figure 4.1 a – b). Neither population 
of the cells we identified expressed traditional adipose macrophage or dendritic 
cell markers such as CD301, F4/80, or CD11c; however, the Ly6CHi Ly6G- cells 
did exhibit heterogeneous expression of MHC-II (Figure 4.1 c).  
PMN-MDSCs can be difficult to distinguish phenotypically from CD11b+ 
Ly6G+ neutrophils. Cells with this surface marker combination only account for 
0.15 ± 0.03% of the total SVF (3.72 x 103 ± 0.77 cells / mL AT) with the majority 
falling into the CD11b+ Ly6CLow Ly6G+ population (67.3 ± 7.0% of total Ly6G+ cells) 
(Figure 4.2).  Furthermore, we believe that these Ly6G+ cells are likely to share 
more functional characteristics with PMN-MDSCs than with neutrophils since other 
groups have shown that there are very few neutrophils in healthy adipose tissue 
[154, 155]. 
Overall, the surface markers expressed by the Ly6CHi Ly6G- and Ly6CLow 
Ly6G+ SVF populations are comparable to those found on tumor-associated M-
MDSCs and PMN-MDSCs, respectively [102]. Since the Ly6C+ Ly6G- cells 
represented a majority of the candidate CD11b+ CD301- CD11c- population, we 




Figure 4.1: CD11b+ CD301- Ly6CHi/Low Ly6G+/- cells are in adipose tissue from 
metabolically healthy mice.  (a) Representative zebra plots depicting the gating 
strategy used to characterize the myeloid cell populations in adipose tissue from 
individual, healthy mice. (b) Quantification of the CD11b+ CD301- populations in 
the stromal vascular cell fraction (SVF) isolated from healthy AT. Adipose from 11 
mice analyzed individually. Error bars represent SEM. (c) Representative 
histograms depicting surface expression of macrophage markers by CD11b+ 
CD301- Ly6CHi Ly6G- cells (Blue line), Ly6CLow Ly6G+ cells (Pink line), or 
Fluorescence-minus one (FMO) controls (dashed line) in healthy AT. Selected 
histograms depict median expression within the group of 11 individuals analyzed. 
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Figure 4.2: PMN-MDSCs make up the majority of Ly6G+ cells in healthy 
adipose tissue. (Left) Overlaid contour plots showing the portion of CD11b+ 
Ly6G+ cells that are PMN-MDSCs in the SVF of healthy mice. (Right) The 
frequency of different cell subsets within the CD11b+ Ly6G+ SVF population. 
Adipose from 4 mice analyzed individually. 
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Adipose-resident CD11b+ Ly6CHi Ly6G- cells express canonical MDSC-
associated genes.  
Simply expressing surface markers reminiscent of tumor-derived MDSCs is 
not sufficient evidence to definitively characterize these adipose-resident cells as 
a genuine population of MDSCs. Because we only recovered 9 - 10 x 103 M-
MDSC-like cells per mL of AT with each sort we were forced to limit the number of 
genes we could probe for. In the tumor microenvironment MDSCs can be 
distinguished from normal monocytes by their co-expression of immunoregulatory 
molecules and cytokines such as arginase (Arg1), inducible nitric oxide synthase 
(Nos2), VEGF, PGE2, IL-4R, IL-10, and TGFβ [100]. We focused our analysis on 
Arg1, Nos2, Il10, and Tgfb1 as these genes are considered “crucial” for MDSC 
biology by Bronte et al (2016) [100]. Traditionally, Nos2 and Arg1 expression are 
used to distinguish “M1” from “M2” macrophages. In tumors however co-
expression of these two enzymes is considered a classic feature of MDSCs. 
Further differentiating MDSCs from monocytes is their active transcription of anti-
inflammatory cytokines such as IL-10 and TGFβ.  
To determine if our adipose-derived Ly6CHi Ly6G- cells were actively 
transcribing these MDSC-associated genes, we isolated RNA from sorted CD11b+ 
Ly6CHi Ly6G- SSCLow cells and performed qRT-PCR. Transcriptional analysis of 
the sorted, adipose-resident CD11b+ CD301- Ly6CHi Ly6G- cells revealed 
abundant transcripts of Arg1, Nos2, and Tgfb1 (Figure 4.3 a). They also expressed 
low levels of Il10 (Figure 4.3 a).  
Intriguingly we also found that these adipose-resident cells were actively 
transcribing Il33 (Figure 4.3 a). This cytokine plays an important role in regulating 
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the immunomodulatory phenotypes of several of the key cell types integral to the 
homeostatic immune network in healthy AT. The cellular source of IL-33  in 
adipose tissue has yet to be identified [31], so finding active transcription of this 
cytokine in our sorted cells definitely raises some interesting questions worth future 
investigations.  
Combined with their surface marker phenotype, the gene expression profile 
of these CD11b+ CD301- Ly6CHi Ly6G- cells further highlights their similarity to the 
Ly6CHi Ly6G- M-MDSCs found in tumors and at sites of chronic inflammation [100]. 
Furthermore, when compared with adipose tissue macrophages, the Ly6CHi Ly6G- 
cells exhibited a distinct expression pattern for immunomodulatory genes such as 
Arg1, Tgfb1, and Il10 (Figure 4.3 b), suggesting that these cells may have a unique 
















Figure 4.3: Gene expression in Sorted CD11b+ CD301- Ly6CHi Ly6G- cells. (a) 
Representative bands from an agarose gel showing active transcription of MDSC-
associated genes in FACS-isolated CD11b+ Ly6CHi Ly6G- cells. Data is 
representative of three independent experiments with AT of 10 mice pooled for 
each experiment. Depicted bands are from the same gel where PCR amplification 
of each gene was tested in duplicate. Gene amplification confirmed using Tbp as 
a housekeeping gene and primer specificity confirmed with non-template controls 
(NTC).  (b) Heat map depicting relative expression of Arg1, Tgfb1, and Il10 by 
FACS-isolated adipose tissue macrophages (ATMs) or CD11b+ Ly6CHi Ly6G- 
cells. Each row represents one independent experiment where AT from 5-10 mice 
was pooled and mRNA was collected from the indicated cell types. Tbp was used 
as the housekeeping gene for each experiment. 
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CD11b+ Ly6C+ Ly6G- AT cells suppress activated T cell responses. 
Given that healthy adipose tissue is constitutively inflamed [13] and contains 
a network of tissue-resident immunomodulatory cells similar to what is found in the 
tumor microenvironment, we hypothesized that the CD11b+ CD301- Ly6CHi Ly6G- 
adipose cells were bona fide, immune suppressive MDSCs. The “gold standard” 
for differentiating MDSCs from monocytes or neutrophils is their ability to suppress 
activated T cell proliferation [100]. To test this, CD11b+ CD301- Ly6CHi Ly6G- cells 
were sorted from the adipose stromal cells of metabolically healthy mice and co-
cultured at a 1:1 ratio with αCD3/αCD28 activated splenocytes for 5 days. The use 
of traditional flow cytometry or radiation-based proliferation assays was not 
feasible, as the small number of CD11b+ CD301- Ly6CHi Ly6G- cells obtained from 
each sort (~ 9 - 10 x 103 M-MDSC-like cells / mL of AT) made it difficult to reliably 
obtain repeatable results with these standard methods. As an alternative, T cell 
proliferation in these co-cultures was assessed using a colorimetric MTT assay 
(Figure 4.4 a). When co-cultured with the isolated Ly6CHi Ly6G- cells and 
stimulated with plate-bound αCD3/αCD28 antibodies, we found that activated 
splenocyte proliferation was significantly attenuated relative to stimulated 
splenocytes alone (PI: 0.38 ± 0.15) (Figure 4.4 b).  
We also co-cultured these adipose-derived cells with MACS-enriched T 
cells in order to verify that they were directly affecting T cell proliferation, and not 
promoting the immune suppressive functions of another cell type present in the 
heterogeneous splenocyte isolate which might, in turn, suppress the T cells. Once 
again, we found that co-stimulated T cells did not proliferate to the same extent as 
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those cultured on their own when they were co-cultured with sorted CD11b+ 
CD301- Ly6CHi Ly6G- cells (PI: 0.22 ± 0.04) (Figure 4.4 c–d).  
Additionally, we correlated the absorbance values from the MTT assay with 
the absolute number of CD4+ T cells in each well, as determined by flow cytometry, 
following 5-day co-culture. We found that the positive control cultures had the most 
CD4+ T cells as well as the highest absorbance values while wells where 
αCD3/αCD28-stimulated T cells were co-cultured with Ly6CHi Ly6G- cells had both 
significantly lower absorbance values and fewer CD4+ T cells, confirming that this 
assay can reliably measure T cell proliferation (R2=0.9957) (Figure 4.4 e). 
Altogether this suggests that these adipose-resident Ly6CHi Ly6G- cells suppress 
activated T cell proliferation. 
These CD11b+ CD301- Ly6CHi/Low Ly6G- cells exhibit many of the requisite 
characteristics of myeloid-derived suppressor cells that accumulate around tumors 
or in chronic inflammatory conditions such as the ability to suppress activated T 
cell proliferation and the co-expression of arginase and iNOS. As such, we believe 
that they are a novel population of MDSCs resident in healthy adipose tissue.  
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Figure 4.4: Sorted CD11b+ CD301- Ly6CHi Ly6G- cells suppress αCD3/αCD28 
activated T cell proliferation. (a – b) Naïve splenocytes were cultured by 
themselves, activated with plate-bound αCD3/αCD28, or activated and co-cultured 
with sorted CD11b+ CD301- Ly6CHi Ly6G- cells. After five days splenocyte 
proliferation was assessed via MTT assay. (a) Representative MTT results. Wells 
depicting each culture condition were selected from a single experiment. (b) 
αCD3/αCD28-stimulated splenocyte proliferation in each co-culture condition was 
assessed after five days by measuring absorbance (Abs) at 450nm. Abs values 
within each experiment were normalized to create a proliferation index (PI) relative 
to the mean Abs of αCD3/αCD28-stimulated splenocytes. Bars represent the mean 
PI from five independent experiments where each culture condition was performed 
in triplicate. Error bars represent SEM. Splenocyte co-cultures MTT plate (c – d) 
Naïve, MACS-enriched T cells were either unstimulated, activated with plate-
bound αCD3/αCD28, or activated and co-cultured with sorted CD11b+ CD301- 
Ly6CHi Ly6G- cells. After five days T cell proliferation was assessed via MTT assay. 
(c) Representative MTT assay results. Wells depicting each culture condition were 
selected from a single experiment. MACS: Magnetic-Activated Cell Separation. (d) 
αCD3/αCD28-stimulated T cell proliferation was assessed after five days by 
measuring Abs at 450nm. Abs values within each experiment were normalized to 
create a PI relative to the mean Abs of αCD3/αCD28-stimulated MACS-enriched 
T cells. Bars represent the mean PI from one of two independent experiments 
where each culture condition was performed in triplicate and the error bars depict 
the SEM among those triplicate wells. Differences between positive control 
cultures and co-cultures with CD11b+ CD301- Ly6CHi Ly6G- cells determined using 
a Student’s t-test. (e) Correlation plot comparing the absolute number of CD4+ T 
cells as assessed by flow cytometry and the absorbance at 450nm in each well 
after being co-cultured for five days. Each marker represents one well from one 
experiment where each condition was performed in triplicate. R2 value derived 
from linear regression. Unstim.: Unstimulated T cells. 
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Potential aMDSC Suppression Mechanisms 
Given the similarities between the tumor and healthy adipose tissue 
microenvironments we wanted to determine if adipose-resident MDSCs (aMDSCs) 
employed immune modulation techniques similar to those of tumor-derived 
MDSCs, such as sequestering essential nutrients, inducing T cell apoptosis, or 
producing anti-inflammatory cytokines. As we were developing our 
proliferation/suppression assay protocols, we performed some pilot experiments 
using CFSE-stained splenocytes. Much to our chagrin, we often found no 
measurable differences in CFSE dilution between the positive controls and our 
aMDSC co-cultures (Figure 4.5 a), suggesting that these cells were not 
immunosuppressive. However, when we counted the total number of T cells in 
each well, we found that there was a greater number of CD4+ T cells in co-cultured 
conditions (8.74x103 ± 0.82 cells/well) after 5 days, than in the unstimulated 
controls (4.69x103 ± 0.13 cells/well) suggesting that aMDSCs did not prevent the 
initial activation and proliferation of naïve splenocytes. However, the aMDSC-
containing co-cultures did have fewer CD4+ T cells on day 5 than the 
αCD3/αCD28-activated splenocyte, positive control cultures (25.66x103 ± 4.97 
cells/well) (Figure 4.5 b).  
These seemingly contradictory suppression results were eventually 
reconciled through the use of the MTT assay format. Even though CFSE dilution 
proved to be an unsuitable means of measuring aMDSC-mediated immune 
suppression, these early experiments did provide some helpful data concerning 
the immunomodulatory mechanism of these cells. T cells co-cultured with sorted 
aMDSCs were clearly proliferating, as indicated by the observed CFSE dilution 
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however, it appeared as if they did not proliferate to the same extent as those 
activated and cultured alone, suggesting that aMDSCs were preventing their 
continued proliferation but not their initial activation. This pattern was consistent 
with two forms of MDSC immune modulation: 1) MDSCs directly induced apoptosis 
in activated T cells or 2) promoted T cell senescence or exhaustion. In the following 
section I briefly summarize some of the experiments we performed to explore this 
question and discuss some of the potential insights that they offer into how 
aMDSCs modulate proliferative T cell responses.   
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Figure 4.5: Compared to controls, co-culture with aMDSCs reduces the 
overall number of T cells, without impeding their initial activation. (a) CFSE 
dilution profile in αCD3/αCD28-stimulated CD4+ splenocytes following 5-day 
culture alone (Blue) or with CD11b+ CD301- Ly6CHi Ly6G- cells (Pink). Histograms 
normalized to mode. (b) % CD4+ T cells in each co-culture condition as calculated 
by FlowJo Proliferation algorithm. (c) CFSE dilution in αCD3/αCD28-stimulated 
CD4+ splenocytes following 5-day culture alone (Blue) or with CD11b+ CD301- 
Ly6CHi Ly6G- cells (Pink). Histograms displaying raw cell numbers in each division 
peak. (d) The absolute number of CD4+ T cells in each well after splenocytes were 
cultured alone or stimulated with plate-bound αCD3/αCD28 and cultured with or 
without sorted CD11b+ CD301- Ly6CHi Ly6G- cells for five days. Bars represent the 
mean number of cells in each well from one of four independent experiments 
where each culture condition was performed in triplicate and the error bars depict 
the SEM among those triplicate wells. 
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Apoptosis Induction: aMDSCs do not induce apoptosis in αCD3/αCD28 
activated splenocytes and T cells.  
First, we investigated aMDSC-mediated cell death using our co-culture 
system, as an increased rate of T cell apoptosis in aMDSC co-cultures could 
explain the significantly reduced number of CD4+ T cells we observed on day 5. 
As before, we set up co-cultures of αCD3/αCD28 activated splenocytes with sorted 
aMDSCs. After 5 days we assessed proliferation via MTT assay. We then stained 
the cells in each well with CD4, CD8, Annexin V, and 7-AAD to quantify the number 
of live, apoptotic, or necrotic T cells in each culture condition via flow cytometry. 
We found that 67.3 ± 6.9% of CD4+ T cells were in the early or late stages of 
apoptosis, 23.6 ± 3.3% were still viable, and 9.1 ± 3.6% were necrotic in the 
positive controls (Figure 4.6). Intriguingly, co-culture with adipose-derived MDSCs 
did not alter this distribution, with 68.3 ± 8.3% of the CD4+ T cells in some stage of 
apoptosis, 23.0 ± 4.8% viable, and only 8.7 ± 3.5% necrotic CD4+ T cells 
respectively (Figure 4.6). This suggests that the aMDSCs were not promoting 
apoptosis in the activated T cells.  
Since the rate of apoptosis was the same between aMDSC co-cultures and 
our positive controls co-culture with aMDSCs we hypothesized that these cells 
were using a more indirect method of suppression and began to pursue other 
MDSC-associated immunomodulatory techniques that could account for the 
delayed onset suppression we were seeing. To this end, we focused our 
subsequent investigations on the nutrient deprivation, cytokine production, and 
oxidative stress mechanisms discussed in the Introduction.  
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Figure 4.6: aMDSCs modulate T cell proliferation without inducing apoptosis. 
Naïve splenocytes were cultured by themselves, activated with plate-bound 
αCD3/αCD28, or activated and co-cultured with sorted aMDSCs. After five days 
splenocyte proliferation was assessed via MTT assay. (Upper) Representative dot 
plots depicting live, early apoptotic, late apoptotic, or necrotic CD4+ T cell subsets 
following 5-day culture of αCD3/αCD28-stimulated splenocytes alone (Left) or co-
cultured with aMDSCs (Right). (Lower) The proportion of live, apoptotic, or 
necrotic CD4+ T cell subsets following 5-day culture of αCD3/αCD28-stimulated 
splenocytes alone (Blue) or co-cultured with sorted aMDSCs (Pink). Bars depict 
the mean percentage of CD4+ T cells that each subset makes up within that culture 
condition from two independent experiments where each co-culture was 
performed in triplicate, then combined for Annexin V and 7-AAD staining and 
analysis. 
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Arginine Sequestration: aMDSC-mediated immune suppression is not 
dependent upon arginase activity.  
A common immunosuppressive mechanism used by MDSCs is arginine 
sequestration. Activated T cells require this essential amino acid to proliferate, but 
do not have the cellular machinery to synthesize it themselves, relying solely on 
they are able to import from their surroundings. Tumor-associated MDSCs 
interfere with this process by upregulating their expression of the arginine-
metabolizing enzymes arginase and iNOS, drastically reducing the bioavailability 
of this amino acid within the tumor microenvironment, arresting any further T cell 
proliferation [107].  
We first examined the importance of arginase activity to aMDSC-mediated 
immune suppression. As before, we set up in vitro co-cultures of αCD3/αCD28 
activated splenocytes with either the total SVF isolate, aMDSC-depleted 
(ΔaMDSC) SVF, or FACS-isolated aMDSCs. To assess the role of arginase, one 
set of these co-cultures were resuspended in our normal culture media while we 
used media supplemented with the arginase inhibitor nor-NOHA (200μM) to 
resuspend the other set. After 5 days we found that blocking arginase activity did 
not affect the proliferative capacity of αCD3/αCD28 activated splenocytes 
(Absorbance of 1.38 ± 0.03 vs 1.32 ± 0.02 at 450nm) (Figure 4.7). Additionally, it 
did not impair the immunomodulatory activity of aMDSCs, as the extent to which 
they suppressed splenocyte proliferation was relatively unchanged by the arginase 
blockade (Untreated vs nor-NOHA PI: 0.85 ± 0.03 vs 0.73 ± 0.03) (Figure 4.7). 
Indeed, save for a slight trend towards enhanced suppression in nor-NOHA treated 
ΔaMDSC SVF (Untreated vs nor-NOHA PI: 0.89 ± 0.07 vs 0.76 ± 0.01) and 
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aMDSC co-cultures, there was no clear difference between the untreated and nor-
NOHA-treated wells for any of the co-culture conditions (Untreated vs nor-NOHA 
PI: 1.2 ± 0.4 vs 1.1 ± 0.08) in terms of T cell proliferation (Figure 4.7), suggesting 
that the immunosuppressive abilities of aMDSCs, and of SVF cells in general, are 
likely not mediated by arginine sequestration.  
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Figure 4.7: aMDSCs do not rely on arginase-mediated nutrient deprivation to 
suppress T cell proliferation. Naïve splenocytes were cultured by themselves, 
activated with plate-bound αCD3/αCD28, or activated and co-cultured with various 
SVF subsets (Blue). nor-NOHA was added to some of the co-cultures to block 
arginase activity (Pink). After five days splenocyte proliferation was assessed via 
MTT assay. P.I. of untreated wells calculated relative to untreated αCD3/αCD28-
stimulated splenocytes and P.I. of nor-NOHA co-cultures calculated relative to 
αCD3/αCD28-stimulated splenocytes cultured in media supplemented with nor-
NOHA. Bars represent the mean P.I. in each well from one of four independent 
experiments where each culture condition was performed in triplicate and the error 
bars depict the SEM among those triplicate wells. 
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Immunosuppressive Cytokines: aMDSC cytokine production was below 
detection levels in vitro. 
We next analyzed the supernatants from these co-cultures using ELISAs to 
look for immunomodulatory cytokines that aMDSCs could be using to slow and 
eventually halt T cell proliferation altogether [100]. Specifically, we focused on IL-
10 and TGFβ as we found that aMDSCs were actively transcribing both cytokines 
in our characterization studies. In supernatants from one experiment we found, as 
one might expect, that IL-10 concentrations were higher in co-cultures with SVF 
(3.68 ± 0.44 pg/mL), ΔaMDSC SVF (2.01 ± 0.98 pg/mL), and sorted aMDSCs (1.96 
± 0.42 pg/mL) than αCD3/αCD28 activated splenocytes alone (< 0.00 pg/mL) 
(Figure 4.8 a). However, these concentrations were at or below the assay’s 5 
pg/mL limit of detection. Using supernatants collected from whole SVF co-cultures 
containing 6 – 7-fold more cells per well, we found a strong correlation between 
the supernatant concentration of IL-10 on culture day 2 and the number of SVF 
cells used to begin with (Figure 4.8 b). As such, we were unable to use to measure 
IL-10 protein levels in the supernatants collected from our subsequent aMDSC co-
culture assays.  
Fortunately, we were able to detect ample levels of TGFβ in these 
supernatants, finding it in every co-culture condition. This suggests including both 
that several different cell types are producing TGFβ in the SVF.  
Intriguingly there was a marked increase in the concentration of TGFβ when 
arginase activity was blocked with nor-NOHA. This was one of the most consistent 
trends we observed across the supernatants we tested and was the most 
90 
pronounced in the co-cultures with activated splenocytes and isolated aMDSCs 
(113.24 ± 8.6 pg/mL vs 173.6 ± 14.0 pg/mL) (Figure 4.9 a).  
When we examined TGFβ concentrations in relation to the MTT proliferation 
results from the respective co-culture, we found a significant positive correlation 
(Pearson Coefficient = 0.7753). Surprisingly, it appeared as if T cell proliferation 
was at its peak in co-cultures with higher levels of TGFβ (Figure 4.9b, blue and 
pink markers). The implications of these findings are somewhat muddied however 
when you consider that whole splenocytes were used as the responding population 
inn these arginase blockade assays. Like the SVF, splenocytes are a 
heterogeneous mix of cells, which, in addition to T cells, contain various types of 
macrophages, dendritic cells, and B cells [156], any of whose function can be 
affected by interacting with MDSCs [89, 102, 107, 114]. It’s possible that our 
aMDSCs are preventing TGFβ production in one or more of these splenic cells, 
causing the drop in TGFβ levels in the aMDSC and ΔaMDSC SVF co-cultures 
compared to our positive controls. Blocking arginase activity could partially restore 
the splenocytes’ ability to produce this cytokine, explaining the increase we see in 
the nor-NOHA treated co-cultures.  
If we focus on just aMDSC co-cultures (Figure 4.9 b, orange markers), we 
see that, contrary to the overall trend, suppression increases (P.I. values 
decrease) as TGFβ levels rise. MDSCs are a very plastic cell type, capable of 
quickly adapting to shifts in their microenvironment. Therefore, it is possible that 
the aMDSCs in our co-cultures upregulated their production of TGFβ in response 
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to the arginase blockade, allowing them to continue to suppress activated T cell 
proliferation.  
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Figure 4.8: IL-10 concentrations were below detection in aMDSC co-cultures 
due to small number of cells in each well. Naïve splenocytes were cultured by 
themselves, activated with plate-bound αCD3/αCD28, or activated and co-cultured 
with various SVF subsets. Supernatants were collected from each well after two 
days and stored at -80° C for later analysis. (a) Mean IL-10 concentrations as 
determined by ELISA. Data derived from the supernatants of one suppression 
assay where each condition was performed in triplicate. The error bars depict the 
SEM among those triplicate wells. (b) Correlation plot of IL-10 concentrations in 
Full SVF co-cultures vs the number of SVF cells plated in each well on day 0. Data 
derived from the supernatants of three independent experiments where SVF was 
co-cultured with αCD3/αCD28-stimulated splenocytes. Each marker represents 
one well. R2 value derived from linear regression. Spln*: αCD3/αCD28-stimulated 
splenocytes. P value obtained using Pearson coefficient. 
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Figure 4.9: aMDSCs may modulate immune cell activity via TGFβ production. 
Naïve splenocytes were cultured by themselves, activated with plate-bound 
αCD3/αCD28, or activated and co-cultured with various SVF subsets. 
Supernatants were collected from each well after two days and stored at -80° C 
for later analysis. (a) Mean concentration of TGFβ as determined by ELISA. Bars 
represent the mean protein concentration from of three independent suppression 
assays where each culture condition was performed in triplicate and error bars 
depict the SEM among those triplicate wells. (b) Correlation plot of proliferation 
index vs TGFβ concentration. Each co-culture condition is represented by a 
different color. Circles denote wells where cells were cultured in normal media and 
X’s represent wells where the media was supplemented with nor-NOHA. R2 value 
derived from linear regression. P value obtained using Pearson coefficient. 
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Conclusions 
According to the nomenclature standards recommended by Bronte et al 
(2016) (ref. 22), a population of cells must fulfill three key requirements in order to 
be classified as MDSCs. First, the myeloid cell population must increase in 
numbers in a pathological setting as compared to healthy conditions. Second, 
these cells should possess a characteristic combination of phenotypic markers, 
which includes surface protein, biochemical, and molecular markers. Finally, and 
most importantly, they need to be able to suppress inflammatory immune 
responses. Our adipose-derived cells are CD11b+ CD301- CD11c- Ly6CHi/Low 
Ly6G+/-, do not express macrophage markers such as F4/80 and CD301, express 
canonical MDSC-associated genes, significantly attenuate activated T cell 
proliferation, and are known to accumulate in the adipose tissue in obesity [129]. 
Taking all of this into account we conclude that these cells represent a bona fide 
population of tissue resident MDSCs within the AT of lean individuals (aMDSCs). 
As for the effector mechanisms behind the immunomodulatory nature of 
these aMDSCs, we can only speculate. Based on our in vitro data, we know that 
aMDSCs abrogate T cell proliferation without preventing their initial activation and 
proliferation. They also do not promote apoptosis in these proliferating T cells. This 
is consistent with other reports documenting their ability to induce senescence in 
activated T cells or regulate their proliferation using methods such as nutrient 
sequestration, cytokine production, and nitrosylation [102, 157]. We performed 
cursory investigations into each but were unable to definitively identify any one of 
them as the primary suppressive method. We believe that, similar to what others 
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have shown, these adipose-resident MDSCs most likely employ a combination of 
techniques in order to stem T cell proliferation [102].  
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CHAPTER 5: MYELOID DERIVED SUPPRESSOR CELLS 
REGULATE T CELL NUMBERS & ADIPOSE MACROPHAGE 
POLARIZATION IN HEALTHY ADIPOSE TISSUE
Once we determined that these cells were bona fide MDSCs, we 
immediately were curious as to what role they were playing in healthy adipose 
tissue, particularly since these cells are typically not found in homeostatic immune 
states. Ideally, to investigate this we would specifically delete MDSCs from the AT 
in vivo and monitor any downstream effects. Unfortunately, the heterogeneous 
nature of MDSCs makes it very difficult to develop either an inducible deletion or 
transgenic knockout model. To date the best method available to remove MDSCs 
in vivo is through the periodic administration of the αGr1 antibody. This monoclonal 
antibody successfully removes all Ly6G positive and a portion of the Ly6C positive 
cells from circulation no matter whether it is delivered intraperitoneally, 
subcutaneously, or intravascularly. We chose to specifically look for changes to 
the T cell and adipose resident macrophage populations as the phenotypes and 
functions of their tumor-associated counterparts are greatly influenced by MDSCs 
[98, 158, 159]. 
Gr-1 Model of MDSC Depletion 
Since I was ultimately interested in how adipose-resident MDSCs 
(aMDSCs) fit into the established immune cell network of healthy tissue, I needed 
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to develop a way to see how the tissue was affected when these cells were taken 
away. Currently, there is no MDSC-specific knock-out mouse model, but there is a 
well-established, antibody-mediated model for in vivo MDSC depletion, which 
utilizes the RB6-8C5 clone of the αGr1 antibody. Historically, this model was first 
used as a means to investigate neutrophil function in vivo [160, 161] but has since 
been adopted by MDSC researchers as a method to study their impact in various 
pathological settings [130, 162-165]. In addition to MDSCs and neutrophils, the 
Gr1 protein is also expressed by subsets of monocytes [162], dendritic cells [166], 
and even CD8+ T cells [167], all of which are susceptible to αGr1-mediated 
depletion. To further complicate matters, the actual depletion efficiency of this 
model varies between different tissue types [168, 169], with additional questions 
even having been raised regarding the standard methods used to verify successful 
depletion [168, 170].  
With no other effective method for MDSC depletion commercially available 
we decided to go ahead with this model as it would allow us to compare the data 
from our experiments with the plethora of data from previously published studies. 
Additionally, we hypothesized that any effects we observed following the αGr1 
treatment would have directly resulted from the loss of aMDSCs in this tissue and 
not from the depletion of these other cells [154, 171, 172], since we would be using 
adipose from healthy, non-obese mice for the initial phase of our study and healthy 
adipose contains very few neutrophils or CD8+ T cells (Figure 5.1).   
Moreover, where we could, we tried to minimize and control for the influence 
of this model’s inherent "messiness”. For instance, the RB6-8C5 Gr1 antibody 
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clone, used for depletion sterically hinders the binding of most Ly6G and Gr1 
antibodies available commercially, which means that neither of these markers can 
be used in conjunction with flow cytometry or fluorescent microscopy to validate 
successful MDSC depletion. As such, we made sure to take this into account when 
we designed the flow cytometry staining panels for the depletion experiments.  
As mentioned above, there is evidence that this antibody is not efficient at 
removing MDSCs from all tissues [169]. To determine whether this model would 
remove aMDSCs from visceral adipose depots, we i.p. injected 4 mice (2 males 
and 2 females) with 200μg of the αGr1 antibody every 3-4 days for two weeks. The 
adipose tissue from these mice was pooled for analysis while their spleens were 
analyzed individually to verify successful MDSC depletion. Initially it appeared as 
if the antibody had not penetrated into the fat pads of these mice as there was no 
real difference in the proportion of aMDSCs in αGr1-treated and untreated SVF. 
However, individual analysis of splenocytes from each of these mice revealed that 
the depletion had only been effective in two out of the four animals, potentially 
explaining the results of our SVF analysis (Figure 5.2). There were two main 
differences between the group of mice where the treatment worked and those mice 
where it didn’t. The primary factor delineating the two groups was sex; the αGr1 
treatment had successfully removed Ly6C+ Ly6G- and Ly6C+ Ly6G+ cells from the 
spleens of the female mice, while these two populations were still present in the 
male spleens. In addition to sex, the female mice weighed significantly less than 
the males, implicating weight as another potential factor involved in determining 
whether or not the antibody treatment would be effective. Since sexually dimorphic 
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differences in antibody-mediated depletion had not been described in the literature 
we concluded that weight was more likely to be the determining factor behind the 
variations in our treatment efficacy. 
With no other MDSC depletion model available we decided to address these 
issues on several fronts. First, we changed the dosing and administration protocols 
to account for weight differences between animals, as well as differences is the 
size and location of the visceral fat pads. We exchanged the standard 
200μg/mouse dose for one that was based on the weight of each mouse (15μg/g). 
In this way we could account for size difference between individuals. 
Additionally, we altered our administration route, moving from 
intraperitoneal (i.p.) to subcutaneous (s.c.) injections in order to address concerns 
regarding differences in fat pad location and size between males and females. The 
SVF cells we harvest in our studies are isolated from the epididymal fat pads in 
males and the parametrial fat pads in females. Although these two pet depots 
serve physiologically analogous functions, anatomical differences mean that the 
fat pads themselves are more superficial in males than those in the females. Their 
location puts them directly in the area targeted in i.p. injections. Since we were 
interested in the treatment’s impact on specifically this tissue, we wanted to avoid 
any potential complications or confounding results that could arise from 
accidentally injecting the antibody directly into the fat pad. We found that s.c. 
administration was just as effective as i.p. injection and improved the consistency 
of the depletion between animals.  
100 
As a final means of optimization, we decided to improve the “resolution” of 
our flow cytometric SVF analyses by modifying our cell isolation protocol. Up until 
this point the vast majority of SVF experiments in our lab were performed to 
investigate its efficacy as a novel cell-based therapeutic. Since the cellular 
composition of the AT immune compartment can be affected by factors such as 
age [173] , sex [174], weight, stress level [175, 176], and even vendor, there can 
be quite a bit of variation among SVF isolates from one healthy animal to the next. 
Using co-housed mice can greatly reduce this variability (Figure 5.3 a), but this 
was not always possible for experiments that require a large number of SVF cells. 
To avoid potential downstream consequences of this variability on experimental 
outcomes, the lab developed a protocol that isolated SVF cells from the adipose 
of 4 – 10 mice that was pooled. Each aspect of this isolation protocol had been 
rigorously and meticulously optimized to maximize the final cell yield and produce 
a consistent, standardized cell isolate. Combining tissues from multiple animals 
yielded a homogeneous cell product that reflected the “average” proportion and 
distribution of each cell type found in the SVF, effectively normalizing the 
composition of the final SVF isolate by erasing the variations observed among 
individual mice.  
Although ideal for functional assays, the normalizing influence of pooling 
tissues from multiple mice was masking some of the more subtle changes that took 
place on an individual level as we observed in our pilot depletion experiments 
(Figure 5.3 a). If we wanted to capture the subtle changes that may result from 
removing such a small population of cells from the AT, we would need to improve 
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the sensitivity of our analyses, so I developed a version of our isolation protocol 
that could reliably isolate SVF cells from the visceral fat pads of a single mouse. 
The new, downsized protocol would allow us to examine MDSC depletion-induced 
changes in AT immune cell dynamics that would have otherwise been masked by 
the homogenization inherent to working with pooled tissue samples. Two major 
modifications to this procedure included using smaller collection vessels and 
minimizing excess plasticware. For example, in the pooled isolation process, the 
adipose tissue is minced and homogenized in a non-tissue culture treated 100 mm 
petri dish. The homogenate is then transferred to a 50mL conical tube for 
collagenase digestion. If this is done is a timely fashion, issues such as losing 
macrophages to plastic adherence are kept to a minimum. However, for the 
individual isolation we would be working with far fewer cells, so we needed to 
eliminate as many steps as possible from the process where cells were transferred 
from one container to another. For the homogenization step this meant mincing 
the whole tissue in the same tube where it would be digested. 
In general we tried to keep the actual collagenase digestion process as 
consistent with the pooled isolation protocol as possible, using the same volume 
of (1 mL / mL AT) and recipe for (2 mg collagenase / mL AT; 1 mg DNase / mL AT; 
and 1mL 0.1% BSA in DCF-PBS / mL AT) the digestion buffer. Additionally, we 
used the same digestion time of 35 minutes for these individual SVF isolations. 
We did find it necessary however to modify the environmental conditions in which 
the digestion took place. In a standard SVF isolation, we use a programmable, 
climate-controlled rotator (Enviro-Genie; Scientific Industries Inc, Bohemia, NY) to 
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control the exact temperature and rotation speed of the tubes during the 
collagenase digestion. However, the smaller 5mL tubes used in the individual SVF 
isolation protocol did not fit in this machine. As an alternative, we digested the 
homogenized adipose samples inside of a cell culture incubator to maintain the 
37°C temperature required for maximum enzyme efficacy. This change in digestion 
environment ultimately introduced two major differences between the individual 
and pooled SVF isolation protocols: CO2 levels and rotation speed. First, the 
Enviro-Genie is not airtight, so pooled tissues are digested at environmental CO2 
levels (0.035%-.1% CO2), while the cell culture incubator maintains CO2 levels at 
around 5%. To minimize the potential for any confounding effects of this difference 
on the digestion process, the tubes containing the tissue and digestion buffer were 
closed and sealed with parafilm in environmental CO2 conditions before being 
placed into the incubator. Switching from the Environ-Genie to the incubator 
presented an additional challenge when it came to proper agitation of the tissues 
during digestion. Previous work in the lab had found that got optimal results from 
the collagenase digestions at a rotation speed of 35 rpm. Unfortunately, digesting 
the tissues in the incubator created a relatively large disparity in the rotation speed 
between the two protocols as the generic blood rotator used to agitate the samples 
had a fixed speed of 18 rpm. These two factors did not seem to influence the 
efficiency of the collagenase enzyme itself as the tissues from both protocols 
appeared to be completely digested after 35 minutes.  
Even with these modifications in place, we were able to procure SVF 
samples from individual mice that were comparable in composition to what we 
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produced with the pooled isolation protocol (Figure 5.3 b). Ultimately, by improving 
our SVF isolation methods, optimizing the αGr1 dose for each mouse, and 
changing how the antibody was delivered, we were able to successfully deplete 
MDSCs from both the spleens and adipose tissue of αGr1-treated mice.   
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Figure 5.1: Healthy adipose tissue contains very few of the non-MDSC cells 
affected by treatment with αGr1. Frequency of CD11b+ Ly6G+ (Ly6G+) cells and 
CD8+ T cells in the stromal vascular cell fraction (SVF) of healthy AT. Each circle 
represents one of eleven healthy mice that were analyzed individually. 
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Figure 5.2: Pooling adipose tissue for analysis masks differences in 
treatment efficacy between individual animals. Healthy, 16 – 20-week old 
C57Bl/6 mice (2 males & 2 females) were treated with αGr1 (200μg per mouse) 
every 3 – 4 days for 1 week. Tissues were harvested and stained for flow 
cytometric analysis. Gonadal fat pads were pooled for analysis (Far Left Column) 
while spleens from each mouse were analyzed individually to verify successful 
MDSC depletion. Dot plots depict the gating strategy used to characterize M-
MDSCs in each tissue. 
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Figure 5.3: Analyzing AT SVF from individuals reveals cage-dependent 
variations in immune cell population distribution.  Healthy, 16 – 20-week old 
C57Bl/6 mice were treated with αGr1 (15μg/g) every 3 – 4 days for 1 week. 
Epididymal fat pads were collected one day after the final antibody injection. (a) 
Dot plots comparing myeloid populations in AT SVF from four αGr1-treated mice 
raised and housed in two separate cages. Values displayed in each plot are 
percentage of CD45+ cells that the specified population represents. (b) The 
absolute number of SVF cells obtained (normalized to the volume of adipose tissue 
harvested) from either pooled (Blue) or individual (Pink) SVF isolation protocols. 
Bars depict the mean of 6 pooled or 19 individual, representative SVF isolations 
performed independently. Error bars denote the SEM. 
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αGr1 effectively removes cells from spleens & adipose after 1 week of 
treatment.  
To the best of our knowledge, this finding represents the first time that 
immunosuppressive MDSCs have been identified in otherwise healthy adipose 
tissue. To better understand the role these adipose-resident MDSCs may play in 
metabolically healthy tissue, we employed an antibody-mediated model of in vivo 
MDSC depletion. Mice received subcutaneous injections of the αGr1 antibody 
(15μg/g) every 3-4 days for one or four weeks. This range of time points allowed 
us to assess both the acute and chronic effects of the αGr1 treatment in the AT. 
One day after their final dose, the epididymal fat pads were collected from each 
mouse and examined individually for any differences in the distribution of the 
various resident immune cell populations using flow cytometry. After 1 week, 
splenocyte analysis confirmed that the treatment had effectively depleted CD11b+ 
CD11c- Ly6CHi/Low Ly6G+/- cells systemically, with the number of these cells 
dropping from 78.0 ± 9.6 x 104 cells/spleen to 5.4 ± 0.9 x 104 cells/spleen (Figure 
5.4 a – b). Following treatment, there was a significant reduction in both subsets 
of adipose-resident of MDSCs (aMDSCs), with a 79.4% decrease in the absolute 
number of Ly6G- M-MDSCs (15.8 x 103 ± 2.4 cells/mL AT vs 3.3 x 103 ± 1.3 
cells/mL AT) and a 95.3% reduction in Ly6G+ PMN-MDSC numbers (3.0 x 103 ± 
0.98 cells/mL AT vs 0.14 x 103 ± 0.06 cells/mL AT) (Figure 5.5 a – b). To determine 
if the changes we observed in the adipose following the αGr1 treatment were non-
specific effects of the antibody treatment, we treated a subset of our mice with rat 
IgG2b isotype antibody (15 μg/g) every 3-4 days for 1 week. There was no 
difference in the proportion of CD11b+ CD301- Ly6CHi/Low Ly6G+/- cells AT SVF 
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cells between the isotype-treated (0.8 ± 0.1%) and untreated (0.77 ± 0.07% of the 
total SVF) animals (Figure 5.6). 
Unexpectedly, we found that the efficiency of αGr1-mediated MDSC 
depletion lessened over time. After 4 weeks of αGr1 treatment, CD11b+ CD11c- 
Ly6CHi/Low Ly6G+/- cells represented 0.6 ± 0.08% of splenocytes (31.85 ± 7.03 
cells/spleen) and 0.31 ± 0.06% of the total SVF isolate (0.95 ± 0.19 cells/mL AT) 
(Figure 5.4 b & 5.5 b). Although inconvenient, this resurgence of CD11b+ 
Ly6CHi/Low Ly6G+/- cells is not unprecedented. A 2016 study by Moses et al [170] 
describes a “Ly-6G+ cell rebound phase” after regular treatment (twice weekly) with 
the αGr1 antibody for more than 10 days. They found that immature, CD11b+ 
Ly6G+ accumulated in the spleens and circulation of mice that received twice 
weekly αGr1 treatments for more than one week. They attributed this effect to 
elevated rates of myelopoiesis caused by increased pressure on the bone marrow 
to replenish the αGr1-depleted cell populations. Gene transcription and flow 
cytometric characterization of these “rebounded” cells revealed that they likely 
served an immunomodulatory function in vivo. Additionally, they refer to, but do 
not show, data directly demonstrating their ability to suppress activated T cell 
proliferation. For our part, we were unable to perform functional characterization 
studies on the CD11b+ Ly6CHi/Low Ly6G+/- cells we found in 4 week αGr1-treated 
mice since we could not feasibly isolate a sufficient number of these cells from the 
SVF of chronically treated animals to set up viable T cell proliferation/suppression 
assays.   However, given their phenotypic similarity to those cells described by 
Moses et al, it is likely that the CD11b+ Ly6Hi/Low Ly6G+/- SVF cells we observed 
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after 4 weeks αGr1 treatment represents a partial restoration of the 
immunomodulatory AT-resident MDSCs. 
Since the RB6-8C5 clone of the Gr1 antibody has also been used to deplete 
neutrophils [160], we assessed the proportion and absolute number of CD11b+ 
Ly6G+ cells in healthy adipose tissue before and after the αGr1 treatment. As 
stated in the previous chapter, we found that CD11b+ Ly6G+ cells only accounted 
for about 0.15 ± 0.03% of the total SVF (3.72 x 103 ± 0.77 cells / mL AT), with the 
majority being Ly6CLow Ly6G+ PMN-MDSCs (Figure 4.2). Following the αGr1 
treatment the percentage of CD11b+ Ly6G+ cells in the total SVF dropped to 0.04 
± 0.02% (0.99 x 103 ± 0.28 cells / mL AT) (Figure 5.7). Given this relative paucity 
of Ly6G+ cells in the adipose tissue of healthy mice, we concluded that any αGr1 
treatment-induced responses in the adipose tissue were most likely directly related 
to the loss of the tissue-resident MDSCs.  
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Figure 5.4: αGr1 antibody treatment efficiently depletes splenic MDSCs. 
Healthy, 16 – 20-week old C57Bl/6 mice were treated with αGr1 (15 μg/g) every 3 
– 4 days for 1 or 4 weeks. Spleens were collected one day after the final antibody
injection. (a) Representative dot plots of splenocytes from healthy, αGr1-treated or 
untreated mice. Circle gates indicate cell populations targeted by the αGr1 
antibody. Selected dot plots for each treatment group derived from one animal, 
representative of the mean of their respective groups. (b) The frequency (Left) and 
absolute number (Right) of splenic MDSCs (Ly6CHi Ly6G- M-MDSCs + Ly6CLow 
Ly6G+ PMN-MDSCs) in untreated (Blue) mice or animals receiving 1- (Pink) or 4-
weeks of αGr1 treatment (Green) mice. Bars depict the mean of 11 untreated, 8 1-
week αGr1-treated, and 6 4-week αGr1-treated mice. Differences between αGr1-
treated and untreated animals determined using a Student’s t-test. *: P < 0.05. 
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Figure 5.5: αGr1 antibody treatment efficiently removes MDSCs from 
epididymal fat pads. Healthy, 16 – 20-week old C57Bl/6 mice were treated with 
αGr1 (15 μg/g) every 3 – 4 days for 1 or 4 weeks. Epididymal fat pads were 
collected one day after the final antibody injection. (a) Representative dot plots of 
CD11b+ F4/80- adipose tissue (AT) stromal vascular fraction cells (SVF) from 
healthy, αGr1-treated or untreated mice. Circle gates indicate cells targeted by the 
αGr1 antibody. Selected dot plots for each treatment group derived from one 
animal, representative of the mean of their respective groups. (b) The frequency 
(Left) and absolute number (Right) of aMDSCs (M-MDSCs + PMN-MDSCs) in AT 
SVF from untreated (Blue) mice or animals receiving 1-week (Pink) or 4-weeks of 
αGr1 treatment (Green). Bars depict the mean of 11 untreated, 8 1-week αGr1-
treated, or 6 4-week αGr1-treated mice. Differences between αGr1-treated and 




Figure 5.6: Generic antibody treatment does not affect the adipose-resident 
MDSC population. Healthy, 16 – 20-week old C57Bl/6 mice were treated with 
IgG2b antibody (15 μg/g) every 3 – 4 days for 1 week. Epididymal fat pads and 
spleens were collected one day after the final antibody injection. (a) 
Representative dot plots of CD11b+ F4/80- SVF cells IgG2b-treated mice. Selected 
dot plot derived from one animal and is representative of the group’s mean. (b) 
The frequency of aMDSCs (M-MDSCs + PMN-MDSCs) in AT SVF from untreated 
(Blue) and IgG2b-treated mice (Pink). Bars depict the mean of 15 untreated or 5 
IgG2b-treated mice from five independent experiments. Differences between 











Figure 5.7: Ly6G+ SVF cells are efficiently depleted following treatment with 
αGr1 antibody. (a) Dot plots characterizing CD11b+ Ly6G+ cell subsets in 
untreated (Upper) and αGr1-treated (Lower) mice. (b) The frequency (Left) and 
absolute number (Right) of Ly6G+ cells in the SVF of untreated (Blue) and αGr1-
treated (Pink) mice. Horizontal bars represent the mean of 8 untreated or 4 αGr1-
treated animals from two independent experiments. Differences between the 
αGr1-treated and untreated animals determined using a Student’s t-test. *: P < 
0.05. 
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Adiposity increases when MDSCs are removed from adipose tissue. 
Although we did not collect extensive metabolic data on our αGr1 treated 
animals, we did weigh them after each injection and weighed their fat pads after 
tissue harvest. These two measures allowed us to calculate a crude percent 
adiposity for each mouse at the end of the experiments. Ultimately, we found that 
the αGr1 treatment did not affect the overall weight of the mice, even after 4 weeks 
of regular injections (Figure 5.8 a).  
Compared to untreated mice, acute αGr1 treatment significantly increased 
adiposity; however, this effect disappears in our 4 week treated mice (Figure 5.8 
b). Without any more detailed metabolic data it is difficult to draw any clear 
conclusions from these findings. Particularly since factors unrelated to our 
treatment, such as environmental changes, altered microbiota, or where they came 
from (in-house colony vs purchased from a vendor), could influence the animal’s 
metabolism and lipid burden. Moreover, there was no change in the number of 
SVF cells per milliliter of adipose tissue which indicates that the treatment was not 
inducing any overt or drastic changes in the tissue’s overall function at any point 
(Figure 5.8 c). Intriguingly, we did find a moderate negative correlation between 
the percent adiposity of an individual mouse and the number of aMDSCs found in 
their adipose, suggesting that aMDSCs may play a role in lipid uptake by 
adipocytes (Figure 5.8 d).  
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Figure 5.8: aMDSC depletion does not affect superficial measures of 
metabolic health or the cellularity of adipose tissue. Healthy, 16 – 20-week old 
C57Bl/6 mice were treated with αGr1 (15 μg/g) every 3 – 4 days for 1 or 4 weeks. 
Epididymal fat pads and spleens were collected one day after the final antibody 
injection. (a) Weight, (b) percent adiposity [(fat pad weight / total weight) x 100%], 
(c) and the absolute number of SVF cells / mL adipose tissue in untreated (Blue), 
1-week (Pink), or 4-week (Green) αGr1-treated mice. (d) Absolute number of 
aMDSCs / mL AT vs percent adiposity. Each circle represents an individual mouse 
from the indicated treatment group. Pearson Coeff.: Pearson Coefficient (derived 
from linear regression. Data pooled from 4 independent experiments.  
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Both acute & chronic MDSC depletion increases the number of T cells in 
healthy adipose tissue. 
In general, the absolute number and proportions of the various AT-resident 
immune cell subsets were unaffected by MDSC depletion, with one notable 
exception: there was a significant accumulation of T cells in the adipose of αGr-1 
treated mice (Figure 5.9 a).  CD4+ T cells make up around 0.8 ± 0.07% of the SVF 
isolate (1.9 ± 0.14 x 104 cells/mL AT) in healthy, 16 – 20-week old male mice. The 
frequency of these cells increased to 1.43 ± 0.3% of the total SVF (3.44 ± 0.6 CD4+ 
T cells/mL AT) after only 1 week of the αGr1 treatment, expanding further to 1.85 
± 0.05% of the SVF (5.28 ± 0.4 CD4+ T cells/mL AT) after 4 weeks of bi weekly 
antibody injections (Figure 5.9 b). Treatment with the IgG2b antibody isotype did 
not affect the CD4+ SVF population, confirming that their accumulation was directly 
related to the loss of adipose-resident MDSCs and was not an off-target effect of 
the antibody treatment itself (Figure 5.10 a – b). 
Additionally, there was no change in splenic CD4+ T cell number (5.01 ± 0.6 
x 106 CD4+ T cells/spleen vs 5.32 ± 0.5 x106 CD4+ T cells/spleen) or frequency 
(9.55 ± 0.5% vs 10.17 ± 0.8%) between 1week-treated and untreated controls, 
indicating that the influx of CD4+ T cells was isolated to the adipose tissue  at this 
early time point (Figure 5.10 c). After 4 weeks of the αGr1 treatment however, the 
percentage (17.5 ± 1.5%) and absolute number (9.07 ± 1.4 x 106 CD4+ T 
cells/spleen) of splenic CD4+ T cells significantly increases, suggesting that 
prolonged MDSC depletion may lead to low grade inflammation systemically.  
Compared to untreated controls, both short-term and long-term αGr1 
treatment significantly reduced the frequency (6.42 ± 0.6% vs 2.9 ± 0.1% vs 2.16 
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± .0.2%) and absolute numbers (3.27 ± 0.2 x 106 CD8+ T cells/spleen vs 1.51 ± 0.1 
x 106 CD8+ T cells/spleen vs 1.13 ± 0.2 x 106 CD8+ T cells/spleen) of splenic CD8+ 
T cells (Figure 5.10 d). This was likely due to the in vivo T cell-eliminating 
properties of the RB6-8C5 clone of the Gr1 antibody [167]. This depleting effect 
did not impact the levels of CD8+ cells in the adipose tissue however, as there was 
not change in their frequency (0.16 ± 0.04% vs 0.19 ± 0.04% of the SVF) and 
number (0.5 ± 0.1 x 104 cells/mL AT vs 0.49 ± 0.04 x 104 cells/mL AT) of these 
cells following short-term MDSC depletion (Figure 5.9 c). Moreover, SVF from 
mice that had undergone chronic MDSC depletion had significantly more CD8+ T 
cells (1.5 ± 0.2% of the SVF & 4.6 ± 0.5 x 104 CD8+ T cells/mL AT) compared to 
their untreated and 1 week treated counter parts (Figure 5.9 c). The Gr1-mediated 
ablation of splenic CD8+ T cells suggested that their accumulation in the adipose 
was more complicated than what we observed with the CD4+ T cells. As such we 
were wary of reading too much into what their presence in adipose could imply.  
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Figure 5.9: MDSC depletion in healthy adipose tissue results in increased 
numbers of T cells.  Healthy, 16 – 20-week old C57Bl/6 mice were treated with 
αGr1 (15 μg/g) every 3 – 4 days for 1 or 4 weeks. Epididymal fat pads and spleens 
were collected one day after the final antibody injection. (a) Zebra plots of depicting 
T cell populations in AT SVF of untreated and αGr1-treated mice. Selected plots 
for each treatment group were derived from one animal and are representative of 
their respective group’s mean. (b – c) Frequency (Left) and absolute number 
(Right) of CD4+ (b) or CD8+ (c) T cells in the SVF of αGr1-treated and untreated 
mice. Data pooled from 4 independent experiments. Bars depict the mean of 11 
untreated (Blue), 8 1-week αGr1-treated (Pink), or 6 4-week αGr1-treated mice 
(Green). Error bars represent SEM. Differences between αGr1-treated and 
untreated animals determined using a Student’s t-test. *: P < 0.05 and NS: P > 
0.05. 
119 
Figure 5.10: αGr1 treatment has differential effects on splenic T cell 
populations. Healthy, 16 – 20-week old C57Bl/6 mice were treated with 15 μg/g 
IgG2b (a – b) or αGr1 (c – d) every 3 – 4 days for 1 or 4 weeks. Epididymal fat 
pads and spleens were collected one day after the final antibody injection. (a) Dot 
plots of T cell characterization in AT of untreated (Left) and IgG2b-treated mice 
(Right). Selected plots for each treatment group were derived from one animal and 
are representative of their respective group’s mean. (b) Frequency of CD4+ T cells 
in adipose SVF. Bars depict the mean of 4 untreated (Blue) or 5 IgG2b-treated 
(Pink) from three independent experiments. (c – d) Frequency (Upper) and 
absolute number (Lower) of splenic CD4+ (c) or CD8+ (d) T cells in αGr1-treated 
and untreated mice. Data pooled from 4 independent experiments. Bars depict the 
mean of 11 untreated (Blue), 8 1-week αGr1-treated (Pink), or 6 4-week αGr1-
treated mice (Green). Error bars represent SEM. Differences between treated and 
untreated animals determined using a Student’s t-test. *: P < 0.05 and NS: P > 
0.05. 
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Accumulated T cells are effector memory T cells. 
T cell accumulation is often an early indicator of the chronic inflammation 
seen in obesity. Specifically, activated CD4+ T cells are one of the first cell types 
to infiltrate the tissue during the early stages of this disease. With this in mind, we 
chose to focus our subsequent studies on comparing our accumulated CD4+ T 
cells to those found in obese animals. Using flow cytometry, we investigated the 
phenotype of these cells following acute and chronic MDSC depletion. In 
agreement with what others have described, we observed a small population of 
CD4+ T cells in the AT of our healthy mice [39, 50]. In contrast however, only a 
relatively small percentage of the CD4+ cells were Foxp3+ regulatory T cells (TRegs) 
[49, 50] (Figure 5.11 a). This disparity is most likely due to the kinetics of TReg 
accumulation in AT, as their population begins to expand around 15-20 weeks of 
age [49, 50]. We chose to use 16-20-week-old mice in the present study as this 
age range is the human equivalent of middle adulthood when obesity often begins 
to develop, while others typically use mice which are 25-30 weeks old. Thus, the 
fewer than expected TReg numbers likely reflects this younger age, as TReg 
populations have not yet begun to expand in the adipose tissue of these healthy 
mice.  
In untreated mice, 86.4 ± 2.41% of the CD4+ T cell compartment in AT was 
composed of Foxp3- CD44+ CD62LLow T effector memory cells (TEM). The 
predominance of the TEM phenotype among CD4+ adipose tissue T cells was 
unaffected by MDSC depletion at any time point (1-week αGr1: 83.9 ± 1.9% of 
CD4+ T cells; 4-week αGr1: 84.8 ± 1.3% of CD4+ T cells) (Figure 5.11 b). However, 
acute and chronic MDSC depletion markedly increased the absolute number of 
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CD4+ TEM in AT from 1.63 ± 0.1 x 104 TEM/mL AT to 2.91 ± 0.6 x 104 TEM/mL AT 
and 4.47 ± 0.3 x 104 TEM/mL AT, respectively, (Figure 5.11 c), indicating that the 
accumulation of CD4+ T cells in the AT of αGr1-treated mice was limited to this 
effector memory subset. 
56.9 ± 4.0% of splenic CD4+ T cells (2.99 ± 0.3 x 106 TEM/spleen) exhibited 
a CD44+ CD62L- TEM phenotype. As in the adipose, there was no change in the 
proportion of TEM within the total CD4+ T cell population  (1-week αGr1: 61.5 ± 8.0% 
of splenic CD4+ cells; 4-week αGr1: 67.4 ± 2.0% of splenic CD4+ T cells) in the 
spleens of αGr1-treated mice compared to controls (Figure 5.12 a – b). This 
suggests that the increased number of CD4+ TEMs in the AT of αGr1-treated 
animals results from the systemic depletion of MDSCs. 
122 
Figure 5.11: Accumulated T cells in adipose following αGr1 treatment are 
effector memory T cells. (a) Dot plots depicting the characterization strategy 
used for CD4+ T cells in AT SVF. Selected plots in each treatment group were 
derived from one animal and are representative of that group’s mean. TCM: Central 
Memory T cells. TEM: Effector Memory T cells. (b) Frequency of CD4+ SVF cells 
that were CD44+ CD62L- TEM. (c) Absolute number of CD4+ TEM in AT SVF. (b – 
c) Data pooled from 4 independent experiments. Bars depict the mean of 11
untreated (Blue), 8 1-week αGr1-treated (Pink), or 6 4-week αGr1-treated mice 
(Green). Error bars represent SEM. Differences between αGr1-treated and 
untreated animals determined using a Student’s t-test. *: P < 0.05 and NS: P > 
0.05. 
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Figure 5.12: The splenic CD4+ CD44+ CD62L- TEM population is unaffected by 
systemic MDSC depletion. (a) Dot plots depicting the CD4+ T cell 
characterization strategy in the spleens of untreated (Upper), 1-week αGr1-treated 
(Middle), and 4-week αGr1-treated mice (Lower). Selected plots in each treatment 
group were derived from one animal and represent the mean within that group. (b) 
The frequency of CD4+ splenocytes that were CD44+ CD62L- TEM. Data pooled 
from 4 independent experiments. Bars depict the mean of 11 untreated (Blue), 8 
1-week αGr1-treated (Pink), or 6 4-week αGr1-treated mice (Green). Error bars 
represent SEM. Differences between αGr1-treated and untreated animals 
determined using a Student’s t-test. NS: P > 0.05. 
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TEMs upregulate expression of markers associated with activation & 
proliferation.  
Most of our knowledge concerning MDSCs comes from studying their 
function within the tumor microenvironment. In this setting αGr1-mediated MDSC 
depletion not only increases the number of T cells infiltrating the tumor [177], it 
also increases their expression of CD69 compared to T cells from non-depleted 
controls [178]. Additionally, CD69 is one of the first markers to be upregulated on 
the surface of T cells after they’ve been activated and has also been associated 
with T cell retention in a peripheral tissue [179]. Relative to their untreated 
counterparts, AT-resident CD4+ TEM rapidly upregulated surface expression of this 
marker after only 1 week of the αGr1 treatment (1.65 ± 0.12 vs 1.0 ± 0.04). CD69 
levels were slightly lower in our chronically treated mice (1.4 ± 0.12) but remained 
significantly elevated compared to adipose tissue TEM isolated from untreated mice 
(Figure 5.13 a – b).  CD69 expression was unaffected by treatment with the IgG2b 
isotype alone (Figure 5.13 c – d).  
Next, we analyzed Ki-67 expression in the AT SVF cells of 1-week αGr1-
treated and untreated mice. Compared to controls (Untreated: 18.05 ± 1.1%; 
IgG2b: 19.02 ± 1.2%), the percentage of Ki67+ CD4+ cells in the adipose 
significantly increased (25.8 ± 0.95%) following MDSC depletion (Figure 5.14 a – 
b). This strongly suggests that these cells are proliferating in situ rather than being 
recruited into the tissue from circulation.  
To further elucidate the activation state of these CD4+ cells, we evaluated 
their transcription levels of classic T cell effector cytokines using qRT-PCR. 
CD11b- CD4+ cells, sorted from the SVF of αGr1-treated and untreated mice were 
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actively transcribing Tnfa at relatively similar levels (Figure 5.15 a – b), while cells 
from αGr1-treated animals showed a trend towards the upregulation of both Ifng 
and Il2 transcription compared to untreated controls. This could indicate that the 
TEM, which accumulate in AT after αGr1 treatment, may have been activated by 
exposure to some constitutively present stimuli within the tissue. However, further 
experiments using single cell RNAseq or intracellular cytokine staining are 
necessary to demonstrate true changes in the functionality of these T cells. Taken 
together it becomes apparent that the adipose-resident MDSCs play a significant 
part in modulating the expansion of the CD4+ TEM population in healthy AT.  
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Figure 5.13: αGr1 treatment, but not IgG2b treatment, increases CD69 
expression on CD4+ TEM in adipose SVF. (a) Representative histogram depicting 
CD69 expression on CD44+ CD62L- TEM in the adipose of untreated (Blue line), 1-
week αGr1-treated (Pink Line), and 4-week αGr1-treated mice (Green Line). 
Selected histograms for each treatment group were derived from one animal in 
each group and are representative of that group’s mean. The dashed line depicts 
the fluorescence-minus one control (FMO) for CD69. (b) The geometric mean 
fluorescence intensity (MFI) of CD69 expression on CD44+ CD62L- TEM in the SVF 
of either 1-week (Pink) or 4-week (Green) αGr1-treated mice relative to untreated 
controls (Blue). Data pooled from 4 independent experiments. Bars depict the 
mean of 11 untreated, 8 1-week αGr1-treated, or 6 4-week αGr1-treated mice. 
Error bars represent SEM. Differences between αGr1-treated and untreated 
animals determined using a Student’s t-test. *: P < 0.05. (c) Representative 
histogram of CD69 expression on CD44+ CD62L- TEM in the SVF of either untreated 
(Blue Line) or IgG2b-treated (Pink Line). Selected histograms for each group were 
derived from one animal and are representative of that group’s mean. The dashed 
line represents the fluorescence minus one (FMO) control for CD69. (d) The 
geometric mean fluorescence intensity (MFI) of CD69 expression on CD44+ 
CD62L- TEM in the SVF of either IgG2b-treated (Pink) or untreated (Blue) mice. 
Data pooled from three independent experiments. Bars depict the mean of 4 
untreated or 5 IgG2b-treated mice. Error bars represent SEM. Differences between 
αGr1-treated and untreated animals determined using a Student’s t-test. NS: P > 
0.05. 
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Figure 5.14: CD4+ T cells in the adipose increase their expression of Ki-67 
following acute MDSC depletion. Healthy, 16 – 20-week old C57Bl/6 mice were 
treated with αGr1 (15 μg/g) every 3 – 4 days for 1 week. Epididymal fat pads were 
collected one day after the final antibody injection. (a – b) Isolated SVF cells were 
stained for Ki67 expression and analyzed using flow cytometry. (a) Representative 
dot plots of CD4+ T cells in adipose tissue (AT) stromal vascular fraction cells (SVF) 
of untreated (Left) and αGr1-treated mice (Right). Gate depicts Ki-67 expression 
by CD4+ SVF cells within each treatment group. Selected plots were derived from 
one animal and are representative of their respective group’s mean. (b) Frequency 
of CD4+ SVF cells that were Ki-67+. Bars depict the mean of 4 untreated and 4 
αGr1-treated mice from 3 independent experiments. Differences between αGr1-
treated and untreated animals determined using a Student’s t-test. *: P < 0.05.  
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Figure 5.15: CD4+ T cells may upregulate IFNγ following MDSC depletion. 
mRNA was collected from CD11b- CD4+ SVF cells isolated from 1-week αGr1-
treated mice. (a) Heatmap of genes expressed by CD11b- CD4+ SVF T cells 
isolated from αGr1-treated mice. Differential expression determined relative to 
untreated controls. (b) qRT-PCR was used to determine their expression of Ifng 
(IFNγ), Tnfa (TNFα), or Il2 (IL-2) relative to CD4+ T cells in the AT of untreated 
mice (Dashed Line). ΔCT calculated relative to Tbp transcription. Each circle 
represents an independent experiment where cells were sorted from the pooled 
SVF of five untreated or five αGr1-treated mice. Differences between treated and 
untreated animals determined using a student’s t-test. *: P < 0.05. 
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Adipose-resident macrophages develop a “mixed” phenotype following 
MDSC depletion. 
In addition to inhibiting T cell proliferation, MDSCs can also modulate the 
function and phenotype of other cells in order to suppress inflammatory responses 
[107]. In the tumor microenvironment, crosstalk with MDSCs promotes the pro-
tumor, immunosuppressive nature of tumor-associated macrophages [114]. Since 
AT-resident macrophages (ATMs) are an integral component of the AT immune 
cell network [20], we investigated whether, similar to the tumor microenvironment, 
adipose-resident MDSCs promoted the “M2”-like, suppressive phenotype of 
ATMs. 
As before, we analyzed the adipose stromal cells from αGr1-treated or 
untreated mice using flow cytometry to detect any overall changes in the make-up 
of the AT myeloid cell compartment. CD11b+ CD301+ MHC-II+ ATMs represented 
13.16 ± 0.9% of the total SVF (3.62 ± 0.4 x 105 cells / mL AT) in healthy untreated 
mice. Both the proportion (1-week αGr1: 13.81 ± 0.9% of total SVF; 4-week αGr1: 
10.67 ± 0.6% of total SVF) and absolute number (1-week αGr1: 3.42 ± 0.4 x 105 
ATMs/mL AT; 4-week αGr1: 3.35 ± 0.3 x 105 ATMs/mL AT) of these cells were 
unaffected by the αGr1 treatment (Figure 5.16 a – b). Similarly, we did not observe 
difference in frequency or number of ATMs in the SVF of IgG2b treated controls 
(Figure 5.16 c). 
Acute MDSC depletion did, however, lead to a marked upregulation of 
MHC-II and CD11c on these cells, as indicated by a significant increase in the 
relative geometric MFI of these two surface markers compared to ATMs from their 
untreated counterparts (MHC-II: 1.0 ± 0.07 vs 2.11 ± 0.31 and CD11c: 1.0 ± 0.02 
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vs 1.35 ± 0.02) (Figure 5.17 a – b). Additionally, there was a trending decrease in 
the MFI of the "M2”-like marker CD301 on the surface of this same population (1.0 
± 0.17 vs 0.55 ± 0.23) (Figure 5.17 a – b). IgG2b treatment had no impact on the 
expression of these surface markers relative to untreated controls (MHC-II: 1.0 ± 
0.1 vs 1.08 ± 0.09 and CD11c: 1.0 ± 0.04 vs 0.92 ± 0.05) (Figure 5.18 a). Notably, 
similar alterations in the expression of these ATM surface markers are hallmarks 
of the immune dysregulation that occurs in the early stages of obesity development 
[21, 29]. 
ATM surface marker expression following sustained, 4-week ablation of 
MDSCs paints a more nuanced picture of AT immune cell dynamics. We found a 
three-fold increase in their expression of MHC-II relative to untreated mice (1.0 ± 
0.07 vs 3.24 ± 0.5) (Figure 5.18 b – c), while CD11c expression dropped from 
what we observed in 1-week αGr1-treated mice and was no longer different from 
the levels in untreated mice (1.0 ± 0.02 vs 0.91 ± 0.07) (Figure 5.18 b – c). The 
restoration of CD11c expression concomitant with increasing MHC-II levels add 
another layer of nuance to our understanding of immune cell dynamics in adipose 
tissue. These results perfectly illustrate the plasticity and adaptability of the 
immune cell network in healthy adipose tissue revealing the dynamic changes 
ATMs can undergo overtime as work to restore of immune homeostasis in the 
tissue. Importantly, the ever-increasing levels of MHC-II on the surface of ATMs 
also demonstrates the integral part MDSCs play in healthy adipose as the 
remaining AT immune cells seem unable to fully return to their original, pre-αGr1 
phenotype. Taken together, this suggests that the adaptability of the immune cell 
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compartment in healthy adipose tissue relies upon the crosstalk between these 
cells and the loss of any single member weakens the whole network. 
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Figure 5.16: αGr1 treatment does not affect the number or proportion of 
adipose tissue-resident macrophages. Healthy, 16 – 20-week old C57Bl/6 mice 
were treated with 15 μg/g αGr1 (a – b) or IgG2b (c) every 3 – 4 days for 1 or 4 
weeks. Epididymal fat were collected one day after the final antibody injection. (a) 
Frequency (Left) and absolute number (Right) of CD11b+ CD301+ adipose tissue-
resident macrophages (ATMs) in the total AT SVF. Data pooled from 4 
independent experiments. Bars depict the mean of 11 untreated (Blue), 8 1-week 
αGr1-treated (Pink), or 6 4-week αGr1-treated mice (Green). Error bars represent 
SEM. Differences between αGr1-treated and untreated animals determined using 
a Student’s t-test. NS: P > 0.05. (b) Representative density plots of CD11c and 
MHC-II expression on CD11b+ CD301+ cells in untreated and αGr1-treated mice. 
Selected plots in each treatment group were derived from one animal and 
represent the mean within that group. (c) Frequency of ATMs in adipose SVF from 
untreated (Blue) or 5 IgG2b-treated (Pink) mice. Data pooled from three 
independent experiments with a total of 4 untreated or 5 IgG2b-treated animals. 
Error bars represent SEM. Differences between treated and untreated animals 
determined using a Student’s t-test. NS: P > 0.05. 
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Figure 5.17: ATM surface marker expression is altered by acute MDSC 
depletion. Healthy, 16 – 20-week old C57Bl/6 mice were treated with 15 μg/g αGr1 
every 3 – 4 days for 1 week. (a) Representative histograms depicting MHC-II, 
CD11c, and CD301 surface expression on CD11b+ CD301+ SVF cells in untreated 
(Blue Line) and 1-week αGr1-treated (Pink Line) mice. The dashed line depicts the 
fluorescence-minus one control (FMO) for the indicated surface marker. Each plot 
depicts one mouse from each group and is representative of the mean within that 
group. (b) Geometric mean fluorescence intensity (MFI) of each surface marker on 
CD11b+ CD301+ ATMs in 1-week αGr1-treated mice (Circles) relative to untreated 
mice (Dashed Line). Horizontal bars represent the mean of 8 αGr1-treated 
animals. Differences between treated and untreated animals determined using a 
Student’s t-test. *: P < 0.05. 
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Figure 5.18: ATMs differentially respond to acute and chronic MDSC 
depletion. Healthy, 16 – 20-week old C57Bl/6 mice were treated with 15 μg/g 
IgG2b (a) or αGr1 (b – c) every 3 – 4 days for 1 or 4 weeks. (a) Geometric mean 
fluorescence intensity (MFI) of indicated surface markers on CD11b+ CD301+ 
ATMs from untreated (Blue) and IgG2b-treated (Pink) mice. Differences between 
treated and untreated animals determined using a Student’s t-test. NS: P > 0.05. 
(b) Representative histograms of MHC-II (Left) and CD11c (Right) surface 
expression by CD11b+ F4/80+ MHC-II+ ATMs in untreated (Blue Line), 1-week 
(Pink Line), and 4-week (Green Line) αGr1-treated mice. The dashed line depicts 
the fluorescence-minus one control (FMO) for the indicated surface marker. Each 
plot depicts one mouse from each group and is representative of the mean within 
that group. (c) MFI of CD11c & MHC-II on CD11b+ F4/80+ MHC-II+ ATMs following 
1 or 4 weeks of αGr1 treatment. Data pooled from four independent experiments. 
Bars depict the mean of 11 untreated (Blue), 8 1-week αGr1-treated (Pink), or 6 4-
week αGr1-treated mice (Green). Error bars represent SEM. Differences between 
αGr1-treated and untreated animals determined using a Student’s t-test. *: P < 
0.05. 
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ATM gene expression is unaffected by MDSC depletion. 
While intriguing, changes in surface marker expression alone were not 
enough to conclude that aMDSCs were controlling the immunomodulatory 
functions of the ATMS. To determine if in vivo MDSC depletion led to functional 
changes in the AT macrophage population, gene expression analysis using qPCR 
was performed on CD11b+ CD301+ MHC-II+ ATMs sorted from the AT SVF of 
either αGr1-treated or untreated mice. Our analysis focused on some of the key 
pro- and anti-inflammatory cytokines associated with ATMs in health and disease 
including TNFα, IL-10, and TGFβ. Although there was a trend towards the 
downregulation of Il10 and upregulation of Tnfa in αGr1-treated ATMs relative to 
untreated controls, there was no significant difference in the overall transcript 
levels of these cytokines between the two groups (Figure 5.19). In obesity, ATMs 
exhibiting surface marker changes similar to those we observed also upregulate 
Arginase transcription. This was not the case for the ATMs we isolated from 
MDSC-depleted mice. Finally, we looked at expression of the transcription factor 
PPARγ, which is strongly associated with the immunomodulatory nature of many 
AT-resident cells including ATMs [180-182]. Again, ATM transcription of this gene 
was unaffected by the loss of MDSCs (Figure 5.19). Taken together, our findings 
suggest that the loss of aMDSCs, in vivo, leads to phenotypical but not functional 
changes in AT resident macrophages; however, further studies using intracellular 
cytokine staining or single cell RNAseq are necessary to definitively determine this. 
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Figure 5.19: ATM expression of immunomodulatory genes remains 
unchanged following αGr1 treatment. mRNA was collected from the CD11b+ 
CD301+ MHC-II+ ATMs isolated from 1-week αGr1-treated mice. (a) Heatmap of 
genes expressed by CD11b+ CD301+ MHC-II+ ATMs isolated from αGr1-treated 
mice. Differential expression determined relative to untreated controls. (b) qRT-
PCR was used to determine their expression of Il10 (IL-10), Tgfb1 (TGFβ), Tnfa 
(TNFα), Pparg (PPARγ), or Arg1 relative to ATMs in the AT of untreated mice 
(Dashed Line). ΔCT calculated relative to Tbp transcription. Each circle represents 
an independent experiment where cells were sorted from the pooled SVF of five 
untreated or five αGr1-treated mice. Differences between treated and untreated 
animals determined using a student’s t-test. *: P < 0.05. 
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Adipose-resident MDSCs regulate whole adipose homeostasis & immune 
cell dynamics. 
Since ATMs and CD4+ T cells represent just two players in a large, 
heterogeneous network of immune cells, we wondered if aMDSCs could be 
interacting with other AT stromal cells in any meaningful way. For these studies 
we examined gene transcription in the full SVF isolate to assess how the loss of 
MDSCs affected the other non-ATM or T cell components of the AT immune cell 
network. Along a similar vein, used explored transcriptional changes in whole 
adipose tissue isolated αGr1-treated mice to get an idea of what was occurring on 
the whole tissue level to determine if dysregulating this network even slightly had 
downstream consequences on the tissue’s health.  
We focused on the key cytokines, enzymes, and transcription factors whose 
transcript levels are known to fluctuate with the inflammatory state of the tissue. 
Surprisingly, we found that, relative to untreated controls, αGr1-treated mice had 
increased transcript levels of immune suppressive cytokines. Il10 and Tgfb1 were 
significantly upregulated in the SVF and AT, respectively, following MDSC 
depletion (Figure 5.20 a – b). Additionally, in the absence of aMDSCs, 
transcription of Il33 was also significantly upregulated in both the SVF and whole 
AT compared to intact controls (Figure 5.20 a – b). This cytokine is of particular 
note since it is heavily involved in regulating the ILC2 – ATM arm of the AT immune 
cell network [30, 31, 182]. However, in both MDSC-depleted SVF and AT, relative 
expression of Pparg was no different from that of untreated mice, similar to what 
we observed with the ATMs.  
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In contrast to this apparent increase in the suppressive nature of the AT 
microenvironment following MDSC depletion, we observed an overall increase in 
Ifng transcript levels in the SVF of αGr1-treated mice, relative to their untreated 
counterparts. This is most likely due to the IFNγ-producing CD4+ TEM that 
accumulate in AT following MDSC depletion (Figure 5.15 b). Interestingly, this 
same transcriptional upregulation is not seen at the whole tissue level (Figure 5.20 
b). However, the transcriptional profile in αGr1-treated mice, at the whole tissue 
level, did exhibit some subtle changes compared to the untreated mice, which 
hinted at the importance of adipose-resident MDSCs in maintaining immune 
homeostasis in the tissue. For instance, we observed a significant downregulation 
of arginase in MDSC-depleted mice compared to untreated controls (Figure 5.20 
b), suggesting that the loss of MDSCs in this tissue triggered a change in the 
immune regulatory activity of other non-stromal AT cells, potentially even within 
the adipocytes themselves. These transcriptional changes we observed at the 
stromal cell and whole tissue level do not necessarily indicate that the absence of 
adipose-resident MDSCs has shifted the AT microenvironment towards or away 
from a more pro-inflammatory state. However, taken together with the alterations 
we found in the size of the CD4+ TEM population size and ATM surface marker 
expression, it is clear that there are vital components of a robust, healthy adipose 
tissue stromal cell compartment.  
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Figure 5.20: Adipose-resident MDSCs regulate whole tissue homeostasis as 
well as adipose immune cell dynamics. (a,b) Heatmap of gene expression in 
the SVF (a) or whole adipose tissue (b) isolated from αGr1-treated (1 Wk #) or 
untreated (Ctrl #) mice. Differential expression determined relative to mean ΔΔCT 
of the untreated controls. Each row depicts expression of the specified gene from 
an individual animal. Grey boxes indicate outliers excluded from differential 
expression analysis. (c,d) Relative expression of specified genes in the SVF (c) or 
whole adipose tissue (d) of untreated (Blue) or αGr1-treated (Pink) mice. Bars 
represent the mean of 8 individual mice whose tissue and cells were processed 
independently. Error bars depict SEM. Significant differences between the two 
groups determined using Student’s t-test. *: P < 0.05 and †: P < 0.06.
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Conclusions 
We believe that we have demonstrated that adipose-resident MDSCs are 
an indispensable member of the immune cell network involved in maintaining AT 
homeostasis. In the absence of these cells the AT resident effector memory T cells 
begin to proliferate showing signs of increased activation with their upregulation of 
CD69. In addition to controlling the size of the adipose tissue TEM population, we 
have evidence that MDSCs have a moderate influence over ATM phenotype. In 
future work it will be interesting to see whether these surface marker alterations 
reflect a larger shift is ATM function as well.  
We chose to focus on the macrophages and accumulated CD4+ T cells in 
healthy AT, as the phenotypes and functions of their tumor-associated 
counterparts are greatly influenced by MDSCs [98, 158, 159]. The increased 
number of CD4+ TEMs, along with the altered expression of "M1" and "M2" surface 
markers on ATMs could suggest that the tissue microenvironment had become 
more "pro-inflammatory" as similar changes in cell phenotype and function are 
well-known hallmarks of the immune dysregulation and inflammation characteristic 
of obesity [154, 183-185]. However, the functionality of these two cell types, as 
assessed by cytokine expression, suggests otherwise. Effector cytokine and 
enzyme transcription in both ATMs and CD4+ TEMs was unaffected by a MDSC 
depletion. 
Additionally, we did not see any conspicuous changes in the inflammatory 
status of AT in these mice. This result was not totally unexpected however, given 
that we were treating healthy animals that were not challenged in any other fashion 
besides the antibody depletion. ATMs and AT TEMs are just two of the many diverse 
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types of cells that make-up the immune cell network mitigating inflammation in this 
tissue [154, 171, 183]. It is likely that they, along with these remaining members of 
the network, actively work to counteract some of the pro-inflammatory effects 
caused by MDSC depletion. Indeed, there was a significant transcriptional 
upregulation of immunosuppressive molecules such as IL-10, TGFβ, IL-33, and 
arginase in the SVF and whole AT of Gr1-treated mice, despite expression levels 
of these mediators remaining unchanged in the sorted ATMs and CD4+ TEMs. 
We did observe some changes in the tissue, that suggests that these 
compensatory responses were not sufficient to re-establish immune homeostasis, 
as CD4+ TEM accumulated and Ifng transcription increased. Additionally, we 
observed a moderate negative correlation between the number of adipose-
resident MDSCs and the adiposity of that individual (Figure 5.8 d), suggesting that 
the loss of MDSCs increases adipocyte lipid burden. Given the wide assortment of 
suppressive effector mechanisms at their disposal [100], MDSCs may modulate 
the function of one or more of the other AT-resident immune cells. The disruption 
of these unidentified interactions by αGr1 treatment and the subsequent 
downstream effects of these missing components of the cell network may account 
for the concomitant pro- and anti-inflammatory responses in the tissue. 
Although adipose-resident MDSCs do not appear to be master regulators 
of immune homeostasis in the tissue, it is clear that AT immune dynamics are 
significantly dysregulated without the AT-resident MDSCs. Their ability to influence 
the immune activities of significantly larger cell populations is not unique among 
immunomodulatory cell types with as few as 30,000 CD8+ “facilitating cells” reliably 
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able to promote the successful engraftment of hematopoietic  stem cells in an 
allogeneic recipient [186]. Additionally, type 2 innate lymphoid cells make up only 
about 1% of the AT SVF cells, yet their depletion has significant negative effects 
the composition of the healthy adipose tissue immune cell compartment [30, 31, 
187]. We propose that aMDSCs are essential players in the complex immune cell 
network in healthy AT, actively preventing the accumulation of CD4+ TEM in this 
tissue and, to a lesser extent, contributing to the stability of the “M2”-like nature of 
adipose-resident macrophages (ATMs), since their depletion leads to increased 
“M1”-like ATM, increased CD11c and MHC-II expression, and reduced CD301 
expression. 
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CHAPTER 6: DISCUSSION & FUTURE DIRECTIONS 
MDSCs as Part of the Adipose Tissue Immune Cell Network 
Adipose is a dynamic tissue that relies on a diverse network of stromal (both 
immune and non-immune) cells to resolve metabolic and tissue remodeling related 
inflammation efficiently. With this project we characterized a novel population of 
adipose-resident MDSCs (aMDSCs) and gained some insight as to their place 
within the greater immunomodulatory cell network of adipose. Based on the 
findings, we propose that aMDSCs are an indispensable part of the AT immune 
compartment in healthy AT, actively preventing CD4+ TEM proliferation in this tissue 
while also contributing to the stability of the “M2”-like nature of adipose-resident 
macrophages (ATMs) (Figure 6.1).  
Our findings suggest that, once in the tissue, aMDSCs integrate seamlessly 
into the homeostatic immune cell network. For instance, we found that, compared 
to untreated controls, ATMs downregulate IL-10 transcription (Figure 5.19) and 
upregulate surface expression of CD11c and MHC-II (Figure 5.17), after acute 
MDSC depletion. Moreover, we found that aMDSCs are actively transcribing IL-10 
(Figure 4.3). This combination of factors is also found in the tumor 
microenvironment, where tumor-associated macrophages engage in constant 
crosstalk with MDSCs via an IL-10-based positive feedback loop [114]. Given that 
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ATMs reduced expression of this cytokine in the absence of aMDSC signaling, it 
is likely that they interact in a similarly cooperative fashion.  
We also uncovered a novel relationship between aMDSCs and adipose 
tissue T cells. When we treated healthy mice with αGr1 we found that the number 
of both CD4+ TEM and CD8+ T cells increased in the adipose. These T cells 
expressed elevated levels of CD69 on their surface and a greater percentage of 
them were Ki67+ compared to untreated controls. Once again this is similar to what 
others have demonstrated in the tumor microenvironment regarding MDSC and T 
cell dynamics [177, 178].  
T Cell Dynamics 
Our findings suggest that, in conjunction with other adipose stromal cells, 
the presence of aMDSCs in the tissue can further temper proliferative responses 
by adipose resident T cells. While this is intriguing in and of itself, it also raises a 
key question about what is triggering these responses to begin with. At first glance 
the adipose-resident T cell reaction to MDSC depletion seems counterintuitive 
given that a foreign antigen or inflammatory stimulus is typically required to incite 
proliferation and neither are present in healthy adipose tissue. However over the 
last decade many have found evidence which strongly implicates an, as of yet, 
unidentified self-antigen as the culprit behind T cell proliferation in healthy adipose 
[142]. One such study demonstrated that CD4+ CD44+ CD62L- effector memory T 
cells were present in the adipose tissue of healthy mice under normal dietary 
conditions [39], suggesting that T cells had previously encountered and mounted 
a response against some adipose-derived antigen.  
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In a broader sense, low-level, self-antigen-induced T cell proliferation has 
also been described before. Adoptively transferred naïve T cells can reconstitute 
the entire T cell compartment in lymphopenic mice [188]. As they circulate these 
cells begin to proliferate, eventually repopulating both central and peripheral 
lymphatic tissues. Two distinct processes known as homeostatic and spontaneous 
proliferation are behind this phenomenon [189, 190]. Homeostatic proliferation 
occurs at a slower rate than canonical, foreign-antigen induced proliferation and 
relies on the availability of cytokines such as IL-7 and IL-15 [189, 191]. Competition 
for these resources is thought to be the signal that determines when the T cell 
compartment within a particular niche is sufficiently repopulated [188].  
Spontaneous proliferation, on the other hand, does not require any 
secondary cytokine signal. This type of proliferation occurs at a much faster rate 
than homeostatic proliferation, with cells dividing multiple times a day instead of 
just once or twice every few days [190, 192]. The resulting T cells also differentiate 
into various subsets of effector and memory T cells, capable of producing 
inflammatory cytokines [40, 190]. 
Despite these major differences, antigen presentation and recognition are 
required for both homeostatic and spontaneous T cell proliferation [188]. 
Reconstitution studies in both Rag knockout and germ-free mice indicate that 
these processes are likely initiated by low affinity interactions with self-antigen 
[191], presented by MHC-II on antigen presenting cells. Intriguingly, this bears a 
striking resemblance to what occurs in the early stages of obesity, where resident 
macrophages and dendritic cells present an unknown self-antigen to tissue 
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resident CD4+ TEM, triggering a cascade of events that eventually leads to chronic 
AT inflammation [193]. In this situation however, the high fat diet itself serves as 
an additional inflammatory stimulus, augmenting the proliferative response of the 
T cells. It is possible that in our MDSC depletion model, the T cells are responding 
to this same self-antigen, but, in the absence of any other inflammatory pressure, 
the size of their population is held in check by mechanisms similar to those which 
control T cell expansion in models of homeostatic and spontaneous proliferation. 
Regardless, these examples of non-foreign, antigen-induced T cell proliferation 
demonstrate that T cell biology is far more nuanced than is often assumed. 
Macrophage Dynamics 
Besides controlling the T cell population and modulating ATM phenotype, 
adipose resident MDSCs likely have beneficial interactions with other cells in the 
tissue. To this end, we examined the expression of immunomodulatory genes in 
whole adipose tissue and within the heterogeneous SVF isolate after acute MDSC 
depletion. We discovered transcriptional changes (Figure 5.20) that, in some 
cases, were unexpected given that expression of these same genes had not been 
affected on the individual cell level in MDSCs, ATMs, and CD4+ TEM cells (Figure 
5.15 & 5.19).  
Importantly, our results do not indicate that aMDSCs are the ultimate 
regulator of immune homeostasis in healthy adipose tissue. Instead they paint a 
much more nuanced picture where the diverse immune cell network in AT is 
constantly monitoring and responding to the dynamic challenges presented by this 
metabolically active tissue. In this proposed working model, the loss of aMDSCs 
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does not have catastrophic consequences, rather it destabilizes the entire network, 
which then adjusts to counteract pro-inflammatory effects. Although this does 
restore a semblance of normalcy to the tissue, there is evidence that this loss has 
a lasting impact on the tissue, as we see with the continued increase in MHC-II 
expression by ATMs and the progressive accumulation of CD4+ TEMs in the tissue, 
despite there being a partial restoration of the aMDSC population.   
Additionally, we observed a moderate negative correlation between the 
number of adipose-resident MDSCs and the adiposity of that individual (Figure 
5.8) suggesting that the loss of aMDSCs increases adipocyte lipid burden. Since 
the animals in this study were only treated for one week, it is tempting to speculate 
that long-term MDSC depletion may lead to increased weight gain on a normal 
diet, when compared to untreated individuals. Furthermore, the alterations we 
observed in the AT of αGr1-treated mice could exacerbate and accelerate the 
development of metabolic consequences induced by high fat diet as these 
symptoms are often preceded by macrophage repolarization and the infiltration of 
activated T cells into the tissue [141].  A recent report found that MDSC depletion, 
concurrent with 8 weeks of high fat diet, increased the severity of diet-induced 
metabolic symptoms as well as TNFα transcription in the tissue compared to high 
fat diet alone [194]. In our study, CD4+ TEM accumulated in the tissue of otherwise 
healthy mice following MDSC depletion. If the Gr1 treatment used in this high fat 
diet study elicited a similar response, then it's possible that the heightened 
metabolic symptoms they observed in treated animals were at least partially due 
to this augmented, initial T cell presence. Taken together with the results of our 
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study, this suggests that the immune dysregulation we observed in healthy AT, 
induced by MDSC depletion, may predispose this tissue to increased inflammatory 
and metabolic consequences when challenged with a high fat diet. 
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Figure 6.1: The Role of aMDSCs in Healthy Adipose Tissue. aMDSCs prevent 
effector memory T cell proliferation (TEM) and promote the suppressive “M2” 
phenotype of adipose tissue-resident macrophages (ATMs) in healthy adipose 
tissue.  
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Caveats to the αGr1 Model of MDSC Depletion 
To investigate the importance of MDSCs in the homeostatic health of AT, 
we employed the classic αGr1 antibody-mediated model of in vivo MDSC 
depletion. This specific model and antibody clone have long been used to 
interrogate the impact of MDSCs in various pathological settings. As discussed in 
Chapter 5, Gr1 is expressed on multiple cell types; however, we were relatively 
confident that the effects we observed in healthy adipose following antibody 
treatment were instigated specifically by the loss of MDSCs and not the depletion 
of other known cellular targets of this antibody such as neutrophils and some 
subsets of CD8+ T cells (Figure 5.1). However, a recent study found that 
eosinophils in an IL-5 rich microenvironment upregulated their surface expression 
of Gr1 (as detected by the RB6-8C5 antibody clone) and Ly6G (as detected by the 
1A8 antibody clone) [195]. Given that adipose resident eosinophils are recruited 
into the tissue via IL-5 produced by ILC2s it’s likely that they also exhibit this 
elevated Gr1/Ly6G expression. If this is the case, then it is possible that our 
antibody treatment may have reduced or depleted eosinophils resident in adipose. 
Their loss within the tissue could offer an alternate explanation for the αGr1-
induced changes we observe following acute treatment, since eosinophils are 
known to promote the "M2"-like nature of ATMs [35]. The inadvertent depletion of 
adipose eosinophils would not however lead to the rapid accumulation of CD4+ 
TEM that we observe in both acutely and chronically treated mice. 
One of our more perplexing observations was the partial restoration of 
MDSCs in the spleens and adipose of mice treated for 4 weeks with αGr1. After 
verifying that the antibody was not defective and switching to a weight-based 
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dosing system, there seemed to be no clear explanation for the incomplete 
depletion we were seeing in the 4 week treated mice. Looking back at the literature 
we soon discovered that in most studies employing this depletion model animals 
only receive one or two injections over a period ranging from 24 hours to 1 week. 
Of the studies that used the antibody for more than a week [196-198], none 
reported the reappearance of the Gr1+ cells they were targeting. In fact, when they 
reported the efficacy of their MDSC depletion, if they did at all, they described 
almost complete ablation of the Gr1+ population. Digging into the details of their 
methodology, I uncovered a common flaw in the verification methods used in both 
acute and chronic αGr1-mediated depletion studies. Often, investigators treat 
animals with the RB6-8C5 clone of the αGr1 antibody, stain collected tissues with 
a fluorophore conjugated version of this same clone, then declare that depletion 
was successful when they don’t find any Gr1+ cells. This however fails to account 
for epitope masking caused by the Gr1 treatment. Ideally the dose used to treat 
the mice should be high enough to evenly distribute the antibody throughout their 
tissues to reach as many of their Gr1 positive cells as possible. If this is the case, 
then the surface of these cells should be saturated with antibody, making the 
surface protein unavailable for binding by additional Gr1 antibodies used to stain 
the tissue. Subsequent analysis via flow cytometry or microscopy would likely 
underrepresent the true number of surviving MDSCs. Others used the 1A8 clone 
of the Ly6G antibody to verify depletion [196, 198], however, previous staining or 
treatment with αGr1 is known to block the Ly6G binding site.  
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A small contingent of investigators have started to call for reform. In 2016 
the Journal of Leukocyte Biology published a paper demonstrating that continued 
treatment with the αGr1 antibody for more than 10 days appeared to induce 
emergency myelopoiesis and severely diminished the antibody’s efficacy [170]. 
This “Ly-6G rebound” only became apparent when they stained tissues and cells 
with a fluorophore conjugated secondary antibody against rat IgG2b, allowing them 
to visualize Gr1+ cells without using the Gr1 antibody. An editorial published in the 
same issue called for a reassessment of the long-term use of this model as well 
as the ways in which we verify it [168, 170]. These warnings seem to have fallen 
on deaf ears however as studies that verify Gr1-mediated depletion by staining for 
Gr1+ cells continue to be published in journals at all levels. 
We believe that the resurgence of MDSCs that we see in our 4 week treated 
mice was not an artifact of insufficient treatment administration nor was it the result 
of a defective αGr1 antibody, since we used a secondary, non-Gr1-associated 
phenotype to characterize and quantify these cells (CD11bHi Ly6CHi CD11c- 
SSCLow). Additionally, our findings corroborate the “Ly-6G rebound effect” 
described by Moses et al (2016), further supporting the need to carefully 
reexamine how the αGr1 depletion model was used in the past and reassess how 
it should be used in future studies. 
Sexual Dimorphism in Healthy Adipose Immune Homeostasis 
Like the majority of studies on the adipose tissue immune cell compartment 
we almost exclusively collected data from male mice. However, there is a growing 
body of literature that is beginning to reveal that anatomically equivalent adipose 
153 
depots may behave differently in males and females [199-203]. For instance, there 
is evidence that the immune "programming" in females is generally more 
suppressive than in males [201, 203]. In the realm of adipose biology this means 
that gonadal adipose depots tend to be less inflamed in female mice compared to 
males when they are fed a high fat diet, containing fewer CD11c+ ATMs and 
expressing lower levels of proinflammatory genes such as Il1b and Nos2 [199]. 
This along with the differences we observed between males and females in our 
pilot αGr1 depletion experiments (Figure 5.2) motivated our initial decision to 
analyze adipose from both male and female mice. Although time restraints 
eventually forced us to focus our investigations on males alone, we did obtain 
partial datasets from both acute (N=4) and chronic (N=6) treatment groups, as well 
as a small cohort of untreated controls (N=3). 
Confirming what we observed in our pilot experiments, acute αGr1 
treatment effectively eradicated MDSCs in the adipose of female mice [12.75 ± 2.7 
x 103 aMDSCs/mL AT vs 0.44 ± 0.05 x 103 aMDSCs/mL AT] (Figure 6.2). 
However, this population had completely rebounded in the adipose of chronically 
treated mice [19.98 ± 2.5 x 103 aMDSC/mL AT] (Figure 6.2).  
The frequency [1.5 ± 0.3% of AT SVF vs 2.23 ± 0.3% of AT SVF] and 
absolute number [4.53 ± 1.3 x 104 CD4+ T cells/mL AT vs 7.37 ± 1.3 x 104 CD4+ T 
cells/mL AT] of CD4+ T cells increased steadily over time (Figure 6.3 a), eventually 
reaching statistical significance after 4 weeks of αGr1 treatment [2.84 ± 0.2% of 
AT SVF; 11.21 ± 1.3 x 104 CD4+ T cells/mL AT], despite the MDSC population 
being almost completely restored (Figure 6.3 a). It is likely that the acute treatment 
154 
 
group would have reached statistical significance given a larger cohort of untreated 
controls as adipose isolated from untreated males in this same experiment 
contained an unusually high number of T cells, potentially due to the stress from a 
recent room transfer within the animal housing facility. Similar to what we found in 
males the majority of these cells belonged to the CD44+ CD62L- effector memory 
subset of T cell (Data not shown). Unlike the males however CD69 expression on 
these cells was unaffected by MDSC depletion (Figure 6.3 b).  
Adipose from untreated female mice contained an almost negligible 
population of CD8+ T cells [66 ± 50 CD8+ T cells / mL AT] which expanded in 
response to MDSC depletion [1 Week: 832 ± 300 CD8+T cells/mL AT; 4 Week: 948 
± 230 CD8+ T cells/mL AT] (Figure 6.3 c). The variation within each cohort 
however is very large and the proportions of CD8+ T cells is relatively small, so it 
is difficult to draw any reliable conclusions from this data. 
We also examined the SVF from female mice for any charges in the resident 
macrophage population. We found that acute and chronic MDSC depletion 
induced a steady increase in the proportion [Untreated: 6.62 ± 0.8% of AT SVF; 
Acute: 8.52 ± 0.9% of AT SVF; Chronic: 10.9 ± 0.8% of AT SVF] and absolute 
number [Untreated: 21.3 ± 6.5 x 104 ATMs/mL AT; Acute: 27.5 ± 2.9 x 104 
ATMs/mL AT; Chronic: 43.8 ± 6.2 x 104 ATMs/mL AT] of ATMs (Figure 6.4 a). 
Both CD11c and MHC-II expression spiked following 1 week of treatment with 
αGr1 [CD11c: 1.0 ± 0.004 vs 1.27 ± 0.04; MHC-II: 1.0 ± 0.05 vs 1.49 ± 0.1]. While 
the relative MFI of these two surface markers drops slightly on the ATMs from 4-
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week treated females it does remain elevated compared to ATMs isolated from 
untreated mice [CD11c: 1.12 ± 0.02; MHC-II: 1.33 ± 0.09] (Figure 6.4 b).  
Although this dataset is incomplete, it does highlight some intriguing 
differences between the adipose immune cell network in males and females. For 
instance, the MDSC rebound in adipose of chronically treated females appears to 
be more robust than what we observed in the males [156.7% vs 60.4% of 
respective untreated aMDSC population]. A study looking at sexually dimorphic 
MDSC responses in viral myocarditis found that females recruited a greater 
number of M-MDSCs into the cardiac tissue than males and that these MDSCs 
demonstrated superior suppressive abilities compared to the equivalent population 
isolated from males [204]. One of the proposed mechanisms for the "Ly6G 
rebound" is that the αGr1 antibody induces emergency myelopoiesis, a process 
that can also recruit MDSCs to the site of chronic inflammation.  
MDSC levels increase in both males and females in the myocarditis model. 
However, females were able to more efficiently recruit highly suppressive MDSCs 
into the inflamed tissue than males, which ultimately improved their survival over 
males. It’s possible that we are seeing a similar differential response in the adipose 
of male and female mice with the females demonstrating their ability to more 
efficiently recruit MDSCs under myelopenic pressure. 
Without functional or gene expression data we cannot really draw any solid 
conclusions much beyond that there does appear to be a sexually dimorphic 
response to MDSC depletion in otherwise healthy adipose tissue. Given our limited 
picture it is tempting to speculate that the slower rate of T cell accumulation, 
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reduced CD69 expression, and expanding ATM population we observed in 
females are all related to their increased capacity to prevent visceral adipose 
inflammation compared to males. 
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Figure 6.2: αGr1 antibody treatment efficiently depletes MDSCs from adipose 
tissue in female mice. (a, b) Healthy, 16 – 20-week old female, C57Bl/6 mice 
were treated with αGr1 (15 μg/g) every 3 – 4 days for 1 or 4 weeks. Uterine horn 
fat pads were collected one day after the final antibody injection. The frequency 
(a) and absolute number (b) of aMDSCs (M-MDSCs + PMN-MDSCs) in AT SVF 
from untreated (Blue) mice or animals receiving 1-week (Pink) or 4-weeks of αGr1 
treatment (Green). Bars depict the mean of 3 untreated, 4 1-week αGr1-treated, 
or 6 4-week αGr1-treated mice. Differences between αGr1-treated and untreated 
animals determined using a Student’s t-test. *: P < 0.05.
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Figure 6.3: MDSC depletion increases the numbers of T cells in healthy 
female adipose tissue. Healthy, 16 – 20-week old female C57Bl/6 mice were 
treated with αGr1 (15 μg/g) every 3 – 4 days for 1 or 4 weeks. Uterine horn fat 
pads were collected one day after the final antibody injection. (a) Frequency (Left) 
and absolute number (Right) of CD4+ T cells in the SVF of αGr1-treated and 
untreated mice. (b) The geometric mean fluorescence intensity (MFI) of CD69 
expression on CD44+ CD62L- TEM in the SVF of either 1-week (Pink) or 4-week 
(Green) αGr1-treated mice relative to untreated controls (Blue). (c) Frequency 
(Left) and absolute number (Right) of CD8+ T cells in the SVF of αGr1-treated and 
untreated mice. Bars depict the mean of 3 untreated (Blue), 4 1-week αGr1-treated 
(Pink), or 6 4-week αGr1-treated mice (Green). (a – c) Data pooled from 3 
independent experiments. Error bars represent SEM. Differences between αGr1-
treated and untreated animals determined using a Student’s t-test. *: P < 0.05 and 




Figure 6.4: αGr1 treatment augments the number of macrophages & changes 
their surface marker expression in female adipose tissue. Healthy, 16 – 20-
week old female C57Bl/6 mice were treated with αGr1 (15 μg/g) every 3 – 4 days 
for 1 or 4 weeks. Uterine horn fat pads were collected one day after the final 
antibody injection. (a) Frequency (Upper) and absolute number (Lower) of CD11b+ 
F4/80+ MHC-II+ adipose tissue-resident macrophages (ATMs) in the total AT SVF. 
(b) The geometric mean fluorescence intensity (MFI) of CD11c (Blue) & MHC-II 
(Pink) on CD11b+ F4/80+ MHC-II+ ATMs following 1 or 4 weeks of αGr1 treatment. 
Data pooled from 3 independent experiments. Error bars represent SEM. 
Differences between αGr1-treated and untreated animals determined using a 
Student’s t-test. *: P < 0.05 and NS: P > 0.05. 
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Translational & Therapeutic Potential 
Recently, one group found that while the overall percentage of CD45+ 
adipose stromal cells was similar in mice, non-human primates, and humans, the 
proportions of various immune cell subsets within that CD45+ population differed 
greatly from one species to the next [205]. Their work raised major concerns 
regarding the translatability of adipose biology studies from the bench into the clinic 
since the immune cell compartment in this tissue appeared to vary so widely even 
between different strains of mice. In our studies we addressed these concerns on 
two fronts. First, we sought to determine whether the presence of aMDSCs in 
healthy mice was consistent between strains or if it was an artifact of our specific 
model. To this end we performed a cursory analysis of the immune cell 
compartment in four male Balb/c mice using our established myeloid and T cell 
staining panels. Similar to the study referenced above, we found that there was no 
difference in the total number of adipose stromal cells [22.7 ± 2.0 x 105 cells/mL 
AT vs 24.7 ± 2.4 x 105 cells/mL AT] between the two mouse strains (Figure 6.5 a). 
There was also no difference in the frequency [0.575 ± 0.06% of AT SVF vs 0.419 
± 0.06% of AT SVF] or absolute number [1.57 ± 0.2 x104 cells/mL AT vs 1.69 ± 0.7 
x 104 cells/mL AT] of aMDSCs in adipose from the C57Bl/6 and Balb/c mice 
(Figure 6.5 b). The adipose from Balb/c mice tended to contain more CD301+ 
ATMs than C57Bl/6 mice [36.23 ± 3.7 x 104 cells/mL AT vs 47.29 ± 14.0 x 104 
cells/mL AT], but this difference was not significant (Figure 6.5 b). However, CD4+ 
T cells did make up a significantly larger proportion of the AT SVF from the Balb/c 
mice compared to the C57Bl/6 mice [1.82 ± 0.4% of AT SVF vs 0.86 ± 0.07% of 
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AT SVF] and, intriguingly, a significantly smaller percentage of this population were 
CD44+ CD62L- TEM [64.4 ± 5.8% of CD4+ SVF cells vs 97.4 ± 0.4% of CD4+ SVF 
cells] (Figure 6.5 c – d). 
Our second way of addressing the translatability of our work was by 
characterizing the stromal cells in samples of human adipose tissue. Samples 
were obtained from patients undergoing routine liposuction procedures and were 
processed in much the same way as our murine adipose samples. Cells were then 
stained and analyzed using flow cytometry. Despite being harvested from a 
subcutaneous, instead of visceral, adipose depot, we identified two myeloid cell 
populations that expressed surface markers characteristic of human M-MDSCs 
(CD11b+ CD33+ HLA-DR- CD14+) and PMN-MDSCs (CD11b+ HLA-DR- CD14- 
CD15+) [100] (Figure 6.6 a – b). Unfortunately, due to time and equipment access 
restrictions we were not able to perform the requisite in vitro functional assays with 
these cells and are therefore unable to draw any concrete conclusions regarding 
their identity as true MDSCs. However, adipose in some form or another is highly 
conserved evolutionarily and from the fat bodies found in insects to the various 
adipose depots in mammals, this metabolically dynamic tissue is consistently 
intertwined with the regulatory branch of the immune system [185, 206, 207]. As 
such it is likely that the two myeloid cell populations, which we identified in human 
adipose, are indeed immunosuppressive MDSCs, involved in moderating adipose 
immune homeostasis.  
In addition to our characterization data, the findings from clinical trials of 
autologous SVF cellular therapies provide further evidence supporting the 
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presence of MDSCs in human adipose. SVF-based therapies have a potent anti-
inflammatory effect when they are used to treat allogeneic transplant rejection. 
Many aspects of this response such as increased angiogenesis or enriched 
populations of TRegs and “M2” polarized macrophages have also been described in 
clinical trials where in vitro generated MDSCs alone are used to treat rejection  [91, 
208, 209]. It is important to note however that the overall anti-inflammatory effects 
of SVF-based therapies most likely results from the combined efforts of all of the 
AT-resident immune cells, as their collective crosstalk preserves the suppressive 
phenotypes of each individual cell once they are introduced into a pro-inflammatory 
microenvironment.  
Moreover, MDSCs resident in healthy human adipose tissue could 
represent a new therapeutic target for diabetes and obesity. These diseases are 
characterized by a disruption in the anti-inflammatory adipose microenvironment, 
mediated by the infiltration of inflammatory immune cells into the tissue. Studies 
have already demonstrated that injections of culture derived MDSCs into obese 
mice increased insulin sensitivity and delayed the onset of metabolic syndromes 
[129]. Determining whether MDSCs play a significant part in maintaining immune 
homeostasis in human AT could help us develop new therapies that designed to 
promote and re-establish homeostatic conditions in obese adipose where the 
immunosuppressive cell network has been significantly degraded.  
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Figure 6.5: Flow cytometric characterization of healthy adipose tissue from 
Balb/c mice. (a) The absolute number of SVF cells obtained (normalized to the 
volume of adipose tissue harvested) from either C57Bl/6 (Blue) or Balb/c (Pink) 
mice. (b) The absolute number of aMDSCs and CD11b+ F4/80+ MHC-II+ 
macrophages (ATMs) in the adipose SVF of C57Bl/6 (Blue) or Balb/c (Pink) mice. 
(c) The frequency (Left) and absolute number (Right) of CD4+ T cells in the SVF 
of αGr1-treated and untreated mice. (d) Frequency of CD4+ SVF cells that were 
CD44+ CD62L- TEM. (a – d) Bars depict the mean of 11 C57Bl/6 or 4 Balb/c mice. 
Error bars denote the SEM. Differences between the C57Bl/6 and Balb/c mice 
determined using a Student’s t-test. *: P < 0.05 and NS: P > 0.05. 
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Figure 6.6: Flow cytometric characterization of healthy human adipose 
tissue. (a) Representative dot plots depicting the MDSC characterization strategy 
used for human adipose tissue stromal vascular fraction cells (SVF). (b) The 
frequency of various immune cell populations in human adipose SVF. Each circle 
represents an individual patient and the horizontal bars represent the mean of the 
data collected from 6-7 patients.   
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FUTURE DIRECTIONS 
This study uncovered an intriguing new layer of the immune cell network in 
healthy adipose tissue; however, there are a few remaining questions that we were 
unable to fully investigate.  
How do adipose-resident MDSCs prevent CD4+ TEM proliferation under 
healthy conditions?  
Peroxynitrite-mediated nitrosylation of T cell receptors (TCR) or MHC-II 
interferes in the antigen recognition process and is also one of the more indirect 
mechanisms by which tumor-associated MDSCs modulate T cell responses [157]. 
These misfolded proteins result from interactions between radical nitrogen species 
and exposed tyrosine residues on the targeted protein. We hypothesized that 
nitrosylation of antigen recognition or presentation machinery could explain the 
delayed onset of aMDSC-mediated immune modulation, since the suppressive 
effects of this process on T cell proliferation increases with increased exposure to 
radical nitrogen species. Unfortunately, we were only able to perform one pilot 
experiment on the SVF from a healthy mouse, but this did yield promising results. 
Using flow cytometry, we found that the CD4+ and CD8+ adipose tissue T cells did 
have more nitrosylated tyrosine residues on their surface than T cells in the 
spleens of these mice (Figure 6.7).  
Although far from conclusive, it is tempting to speculate that this 
nitrosylation was a direct result of their proximity to aMDSCs. If time had allowed 
it would definitely have been worthwhile to investigate the nitrosylation state of the 
CD301+ ATMs isolated from the SVF of αGr1-treated mice as I suspect that the 
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sudden reinstatement of functional antigen presentation machinery may be a large 
factor in the rapid accumulation of T cells following in vivo MDSC depletion. 
Additional support for this hypothesis can be found in the literature on T cell and 
macrophage dynamics in the early stages of obesity development. These studies 
have found that the initial accumulation of CD4+ inflammatory T cells is triggered 
by an endogenous adipose antigen [210] that is presented to these ATMs in an 
MHCII-dependent fashion [142]. If we plug our observations from the MDSC 
depletion experiments into this working model, it would suggest that aMDSCs in 
healthy adipose modulate the functionality of antigen presentation machinery on 
AT macrophages, impeding their ability to inadvertently reactivate AT resident TEM. 
To determine if aMDSC-mediated nitrosylation of antigen presenting and 
recognizing proteins prevents TEM activation and proliferation, we would expand 
the preliminary line of investigation to include αGr1 depletion experiments for one 
or four weeks. SVF cells would be stained with T cell and macrophage markers 
along with the N-tyrosine antibody used in our pilot experiments. Analyzing these 
samples on an Image Stream would allow us to detect colocalization of nitrosylated 
tyrosine residues on T cell receptors and MHC proteins. Additional staining could 
be used to assess whether MDSC-depletion increases surface expression of CD3ζ 
or IL-2R on adipose tissue T cells, as these two proteins are directly involved in 
antigen-mediated responses and lose functionality as a result of aMDSC 
nitrosylation.  
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Figure 6.7: Macrophages, but not T cells have nitrosylated surface proteins 
in healthy adipose SVF. (a) Contour plot comparing CD4 and CD8 expression on 
nitrosylated tyrosine (N-tyrosine) positive SVF cells (Blue) versus the whole SVF 
isolate (Pink). (b) Overlaid histograms showing N-tyrosine on the surface of CD4+ 
SVF T cells (Blue). Unstained SVF T cells (Pink) back-gated based on similar size 
and granularity (FSC-A vs SSC-A) to CD4+ SVF. (c) Contour plot comparing 
CD11b and CD301 expression on N-tyrosine positive SVF cells (Blue) versus the 
whole SVF isolate (Pink). (d) Overlaid histograms showing N-tyrosine on the 
surface of CD301+ adipose tissue macrophages (ATMs) (Blue). Unstained SVF 
(Pink) back-gated based on similar size and granularity (FSC-A vs SSC-A) to 
CD11b+ CD301+ ATMs.  
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What recruits MDSCs to healthy adipose tissue? 
The current thinking on MDSC genesis is that TLR activation recruits 
circulating monocytes into the tissue or tumor, where they encounter a second TLR 
agonist, in addition to immunomodulatory signals such as IL-10 and TGFβ. This 
combination of pro-and anti-inflammatory stimuli "reprograms" the monocyte, 
causing it to acquire immune suppressive functions [93]. In vivo, conditions such 
as these typically occur at sites of chronic inflammation where pro-inflammatory 
Type I responses react to an insult, while tissue remodeling Type II responses 
attempt to repair and prevent further damage to surrounding tissue. As discussed 
in the Introduction, a surprisingly similar microenvironmental setting can be found 
in healthy AT (Figure 6.8). This tissue is constantly remodeling to accommodate 
for fluctuations in adipocyte size as they store and release lipid [13]. The TNFα-
mediated degradation of the extracellular matrix required for these dynamic 
structural changes [13] may provide a constitutive source of TLR agonists such as 
biglycan and decorin [15]  which are recognized by TLRs 2 and 4. Once recruited 
into the tissue, circulating monocytes would encounter the suppressive network of 
AT-resident immune cells, including aMDSCs, which would provide the secondary 
immunomodulatory signals, such as IL-10, IL-13, and TGFβ, needed to promote 
their reprogramming [29, 154]. This homeostatic oscillation between acute 
inflammation and its rapid resolution creates an ideal niche for a population of 
tissue resident MDSCs to thrive.  
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Figure 6.8: Proposed model for MDSC recruitment into healthy adipose 
tissue.  
1) Adipocyte lipolysis or lipogenesis induces the breakdown of the extracellular
matrix (ECM). By-products of ECM remodeling can trigger toll-like receptors on
circulating monocytes, recruiting them into the tissue.
2) Monocytes encounter pro-inflammatory signals from further TLR stimulation or
produced by effector memory T cells (TEM).
3) The abundance of immunomodulatory cytokines found in healthy adipose
tissue provide concurrent anti-inflammatory signals to the monocyte.
4) The combination of pro- and anti-inflammatory stimuli reprograms the
monocyte to adopt a suppressive MDSC phenotype.
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What is the relationship between MDSCs and metabolic disease? 
For almost a decade the relationship between MDSCs and obesity has been 
a subject of interest for those investigating alternative therapies for metabolic 
disease [97, 129, 130, 211]. Our work has introduced another layer to this by 
demonstrating that MDSCs are constitutively present in healthy adipose tissue and 
not just the inflamed adipose of obesity as described by others. However, if these 
cells accumulate during obesity and the severity of metabolic symptoms negatively 
correlates with the number of MDSCs in the tissue [129], then why does adipose 
become inflamed in the first place and why does chronic high fat diet exacerbate 
this inflammation even as the MDSC population expands? 
One possibility is that the increasingly pro-inflammatory conditions that 
develop in adipose tissue during high fat diet force their differentiation into “M1”-
type macrophages. Several lines of evidence from tumor and adipose biology 
support this consideration. First, the repolarization and forced differentiation of 
MDSCs into pro-inflammatory macrophages and dendritic cells has been 
described as a possible strategy in overcoming their potent suppression of anti-
tumor immune responses [212]. Second, further supporting this idea is the 
accumulation of CD11c+ monocyte derived “M1” macrophages in obese adipose 
tissue [20]. Pro-inflammatory cues recruit circulating monocytes into the adipose 
which then differentiate into mature antigen presenting cells, capable of inciting 
inflammatory T cell responses. Third, these same factors can cause normally 
suppressive, ATMs to shift towards an “M1” phenotype themselves [29]. This 
indicates that pro-inflammatory cues within the adipose microenvironment recruit 
inflammatory cells and actively affect the functional phenotypes of both recruited 
171 
and tissue resident cells. Altogether these studies demonstrate the functional 
plasticity of MDSCs as well as their sensitivity to shifts in microenvironmental cues. 
Given MDSC plasticity, it is likely that chronic exposure to the pro-inflammatory 
microenvironment within obese adipose tissue ultimately leads to their 
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